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ABSTRACT 
 Persistent HBV infection carries an elevated risk of developing cirrhosis and 
hepatocellular carcinoma (HCC). Infection is preventable by immunisation with a recombinant 
protein vaccine encompassing the major surface antigen (HBsAg) of Hepatitis B virus (HBV). 
The vaccine is globally administered resulting in a notable decrease in global carrier rates. 
However, some recipients (5-10%) remain as hypo- or non-responders associated with minimal 
to no protective antibody levels. HBV-specific DNA-vaccines have demonstrated potential for 
induction of potent antibody responses and target-specific activation of cellular immunity with 
purported application in chronic HBV infection (CHB) treatment. Furthermore, in situ 
production of HBsAg allows for inclusion of neutralising and cross-specific preS epitopes absent 
from the current vaccine. Immunisation with mRNA accompanies a superior safety profile and 
offers several other advantages over DNA, but no such vaccine targeting HBV exists. To develop 
an anti-HBV mRNA-based vaccine, vectors engineered for mRNA production were constructed. 
From the production vectors, LHBs (large HBsAg) and SHBs (small or major HBsAg) mRNA 
was synthesised by in vitro transcription using phage T7 polymerase, and translated in 
transfected cells to produce detectable LHBs and SHBs. SHBs was readily secreted while LHBs 
was retained intracellularly. This investigation constitutes a preliminary step towards the 
preclinical development of an anti-HBV mRNA-based prophylactic and therapeutic vaccine 
formulation and has provided proof-of-principle that LHBs encompassing preS epitopes is 
expressible in situ from synthetic mRNA transcripts. Further developments will include 
modification of the mRNA synthesis protocol to comply with GMP regulations and functional 
testing of the vaccine candidate in appropriate animal models. 
              
Keywords: HBV, HCC, HBsAg, preS, DNA-vaccines, CHB, mRNA-based vaccine 
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1. INTRODUCTION 
 
1.1 Molecular Virology of HBV 
 
HBV is a relatively small, enveloped, non-cytopathic virus with a partially double-
stranded, relaxed circular DNA (rcDNA) genome of approximately 3.2 kilobases (kb) (Summers 
et. al., 1975). HBV was first visualised as a 42-nm viral particle by electron microscopy, 
sometimes referred to as the Dane particle (Dane et. al., 1970). Dane particles consist of a 
nucleocapsid core, housing the genomic material and viral polymerase, enveloped in a host-
derived lipid envelope embedded with surface glycoproteins. The genome is packaged into an 
icosahedral nucleocapsid (Seeger & Mason, 2000) with a triangulation number T=4 or T=3 
(reviewed in: Steven et. al., 2005). The rcDNA genome has a negative strand, the coding strand, 
and a non-coding positive strand of incomplete length. The HBV genome is produced from a 
pregenomic RNA (pgRNA) replicative intermediate by reverse transcription during capsid 
assembly and maturation. Reverse transcription is the function of a viral-derived polymerase (P) 
co-encapsidated with the pgRNA template during virion assembly. Within infected cells, the 
rcDNA is translocated to the nucleus where it is converted to a highly stable, episomal covalently 
closed circular DNA (cccDNA) minichromosome (reviewed in: Seeger & Mason, 2000).  
The cccDNA serves as the transcriptional template of HBV and encodes the structural 
and non-structural proteins essential for the completion of the replication-cycle. Viral proteins 
are produced from four overlapping open reading frames (ORFs) that complete the HBV genome 
(Figure 1). Unidirectional transcription of the cccDNA template yields four viral mRNAs which 
are subsequently translated into seven viral proteins (Moolla et. al., 2002). All mRNA transcripts  
17 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Organisation of the HBV genome and transcription products of the HBV surface antigen (PreS1/PreS2/S) gene. Schematic 
of the linearised genome, the genome is normally circular. The four ORFs of the HBV genome are the Core, Surface, X and P. All 
four mRNA transcripts share a polyadenylation sequence at the 3’ end (indicated in red). The S ORF is transcribed into the 2.1kb and 
2.4kb transcripts encoding the major (S) HBs and large (L) HBs proteins respectively. Differential processing of the 2.4kb transcript 
during mRNA maturation forms the mRNA for the middle (M) HBs protein.  
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terminate at a polyadenylation signal located at the shared 3’ end (Figure 1). A recombination 
event in the nucleus can sometimes result in the random integration of HBV genomic DNA into 
host chromosomes (Wang & Rogler, 1991; Sung et. al., 2012). Episomal persistence of cccDNA 
or integrated HBV genomic elements within an infected liver establishes chronic infection and 
the consequent continual production of HBV antigens acts to drive the immunotolerant 
phenotype. 
The four mRNA transcripts produced from cccDNA include three subgenomic transcripts 
of 2.1kb, 2.4kb and 0.9kb, translated into the surface antigen (HBsAg) glycoproteins (2.1kb and 
2.4kb) (Figure 2a) and HBx protein (0.9kb). The surface antigen glycoproteins occur in three 
forms: small surface antigen (SHBs), middle surface antigen (MHBs) or large surface antigen 
(SHBs). The surface glycoproteins occur at varying frequencies within the HBV envelope and 
can undergo post-translational glycosylation or myristoylation with effects on protein function 
(see Section 1.2.1). Spherical and filamentous subviral particles (SVPs) noted alongside the 
Dane particles in electron micrographs have been determined to be secreted particulate matter of 
HBsAg (Dane et. al., 1970). The SVPs are non-infectious and form the basis of clinical detection 
and disease monitoring in HBV-infected patients. 
The second class of mRNA transcript produced is the greater-than-genome-length 
pgRNA transcript which functions as the genomic template during viral replication and is 
translated into the core (HBcAg), precore (HBeAg) and HBV polymerase (P) proteins (Nassal et. 
al., 1990). The 25-kDa HBeAg precursor protein or precore protein (Ganem, 1996; Seeger & 
Mason, 2000) is processed in the endoplasmic reticulum (ER) to give the secreted HBeAg of 
17kDa (Ou, 1997). Detection of HBeAg is used as a diagnostic marker for high infectivity 
(Hollinger, 1996). HBcAg and HBeAg are both variants of the core protein where HBcAg 
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contributes to nucleocapsid assembly and HBeAg is readily secreted with a proposed function in 
promoting immune tolerance (Chen et. al., 2004). P initiates reverse transcription via interactions 
with the pgRNA and covalently associates with the negative strand (Pollack & Ganem, 1993). 
Once within the nucleocapsid, P reverse transcribes the pgRNA in situ to give the rcDNA form 
of the genome. 
The function of the HBx protein in the viral replication-cycle is not well defined and 
remains a topic of debate. Recently it was determined that HBx binds structural maintenance of 
chromosome (SMC) complex proteins 5/6 (SMC5/6) targeting them for ubiquitination and 
subsequent proteosomal degradation (Murphy et. al., 2016). SMC5/6 proteins recognise and bind 
extrachromosomal DNA with inhibitory effect on gene expression. Degradation of SMC5/6 
results in their inability to bind cccDNA and prevent the expression of HBV proteins. HBx may 
indirectly regulate HBV replication by this mechanism.  
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Figure 2: Translation products of the HBV surface antigen (preS1/preS2/S) gene. a) Domains of 
the LHBs protein. LHBs protein includes preS1/preS2/S protein domains, MHBs includes only 
preS2/S and SHBs or major HBsAg encompasses only the S protein region. The roman numerals 
indicate the placement and numbered identity of the putative transmembrane domains in the 
shared S domain. b) Functional organisation of the LHBs protein. The myristoylated N-terminal 
domain is required for PM-association. PreS1 (aa 2-48) mediates NTCP-binding with a 
conserved motif (9-NPLGF(F/L)P-15) playing a crucial role in entry receptor association. The 
NC-binding region (aa 75-164) of preS1/preS2 functions in envelopment of the virion. TM helix 
I contains 3 (φ) hydrophobic clusters implicated in membrane fusion. The ‘a’ determinant within 
the AGL between TM II and III is a primary determinant of infectivity and is structurally 
maintained by disulphide bridge formation (not shown).  
a) 
b) 
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1.1.1 Surface Antigens of HBV 
 
The LHBs, MHBs and SHBs proteins have distinct and diverse functions in the 
completion of the HBV replication-cycle and the propagation of infection. All three isoforms 
have a common C-terminal domain (S domain) which is responsible for embedding the protein 
into the viral envelope via the four putative transmembrane helical domains (Figure 2b). The 
preS1 and preS2 domains are N-terminal extensions of the major HBsAg (SHBs). PreS1 and 
preS2 function in mediating specific interactions with the nucleocapsid during envelopment and 
virion release (Nassal, 1996) as well as entry receptor-binding (Le Seyec, et. al., 1999; Glebe, et. 
al., 2003; Barrera et. al., 2005). Only recently, Yan and colleagues identified the sodium 
taurocholate co-transporting polypeptide (NTCP), a hepatocyte-specific bile salt transporter, as 
being the entry receptor for HBV and HDV (Yan et. al., 2012). A highly conserved, 75-amino 
acid (aa) region (aa 157-165; Figure 2b) in the preS1 domain of LHBs mediates virion binding to 
the NTCP entry receptor. Differing lengths of the preS-binding regions in MHBs and LHBs 
impart different affinities to NTCP indicating that the entire 75-aa region of preS1 (Figure 2b) 
may also participate in NTCP association (reviewed in: Urban, et. al., 2014).  
Initially, LHBs is internalised within the viral particle and is therefore not available for 
receptor binding. Myristoylation of the N-terminus of LHBs (Persing et. al., 1987) results in 
subsequent post-translational translocation (Lambert & Prange, 2001) exposing the preS-binding 
domains on the external surface of the mature virion. N-terminal myristoylation, therefore, is a 
crucial determinant of HBV infectivity (Gripon et. al., 1995; Bruss et. al., 1996). Le Seyec and 
colleagues mapped functionally important sites within the preS domains in HBV subgenotype D 
(Le Seyec et. al., 1998). They found that mutations within the first 77 amino acids of LHBs 
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completely blocked infectivity while mutations within the preS2 domain and preS1 (aa 114-163) 
disrupted capsid assembly and could not be conclusively classified in terms of infectivity (Figure 
2b). The generation of broadly neutralizing antibodies against LHBs alone could potentially 
eliminate binding to surface entry receptors. In this study, LHBs and SHBs proteins were 
evaluated further. 
Other determinants of infectivity include the antigenic loop (AGL) protein region located 
between TM-I and TM-II of the S domain in all three forms of HBsAg (Figure 2b). An alanine-
scanning mutagenesis approach was used by Salisse and Sureau to map a set of highly conserved 
residues within the AGL that are critical for infection, namely the ‘a’ determinant (Salisse & 
Sureau, 2009), the first discovered marker of HBV infection (Blumberg, 2002). The 
conformation of the AGL, as dictated by disulphide bridge formation between Cys-121 and Cys-
149 (Figure 2b), is a determinant of the structure of the ‘a’ determinant (Abou-Jaoudé & Sureau, 
2007). This sequence is currently the most effective neutralisation epitope included in the 
broadly administered anti-HBV vaccine (Zanetti et. al., 2008). Disruption of the disulphide 
bridge conformation by membrane-impermeable reducing agents negated infectivity (Abou-
Jaoudé & Sureau, 2007).  
Upon gaining entry into a cell and becoming exposed to the reducing cytoplasmic 
environment, dissolution of the disulphide bridges of the ‘a’ determinant may function in a post-
binding stage of infection. A similar mechanism has been proposed for the infection pathway of 
duck HBV (Grgacic & Schaller, 2000). The structure of the disulphide bridges in duck HBV 
maintains the HBsAg in a so-called pre-fusion state (Grgacic & Schaller, 2000). A highly 
hydrophobic protein domain comprising 3 hydrophobic (φ) clusters embedded in the TM-I 
domain of LHBs in duck HBV is crucial for the fusion of viral and cellular membranes during 
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infection (Chojnacki et. al., 2005). A similar region has been found in human HBV (Lepère-
Douard et. al., 2009) though the exact mechanism of membrane fusion in human infection 
remains to be completely characterised. The φ clusters role in infectivity, though, appears 
restricted to the LHBs despite being found in all three isoforms.  
In summation, the determinants of HBV infectivity are confined to the surface antigen 
proteins and include (i) crucial sequence regions in PreS1, (ii) N-terminal myristoylation of 
LHBs, (iii) φ clusters of LHBs, (iv) the AGL region and (v) the ‘a’ determinant within the AGL. 
Compromising the determinants of infectivity could serve a prophylactic and therapeutic 
purpose.  It is reasonable to assume that anti-preS1 antibodies, therefore, would be neutralizing 
and highly protective. Evidence in support of this approach stems from other studies wherein 
direct interference of receptor binding by a synthetic preS1-derived lipopeptide effectively 
blocked HBV infection (reviewed in: Urban et. al., 2014). The synthetic peptide, Myrcludex B, 
is currently being evaluated in phase 2 clinical trials.  
 
1.2 HBV Infection 
 
Historically, hepatitis has been a recognised clinical condition for many centuries, typically 
presenting as jaundice. An outbreak of hepatitis in 1883 in Germany following a national 
smallpox immunization campaign marked the first documented cases of a parenterally 
transmissible form of the condition (Lurman, 1885). It was only in the 1940’s that the viral 
aetiology of hepatitis was first described identifying two main routes of transmission, faecal-oral 
or through exposure to contaminated blood products (reviewed in: Van Damme et. al., 2013). 
Faecal-orally transmitted hepatitis is now universally referred to as Hepatitis A infection while 
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parenteral infection is now accepted as being caused by Hepatitis B virus (HBV). An important 
landmark was reached in HBV research when, in 1965, Blumberg and colleagues accidentally 
isolated the surface antigen, or so-called ‘Australian antigen’, of HBV (HBsAg) by 
isoprecipitation (Blumberg, 2002). 
HBV is the prototypical member of the family hepadnaviridae consisting of hepatotropic 
viruses with a relatively narrow range of host specificity. HBV causes significant liver injury in 
primates and humans while other hepadnaviridae infect avian or rodent hosts (Seeger and 
Mason, 2000). Such a select host range often complicates HBV experimentation and the 
development of novel therapeutics because of limited access to animal models representative of 
the human disease. There are many questions regarding HBV immunopathology and disease 
progression that remain to be elaborated.  Despite the associated challenges, global efforts have 
deepened the understanding of natural HBV history, aetiology, epidemiology and molecular 
biology all with the aim of eventual eradication of the virus from the human population. 
 
1.2.1 Immunopathology of Acute and Chronic HBV Infection 
 
HBV is one of five distinct viral agents known to cause hepatitis in humans and HBV 
infection is recognised as being responsible for the majority of the global hepatitis disease 
burden. Usually, acute infections are spontaneously resolved by the host adaptive and innate 
immune responses. However, approximately 5% of infected adults (~ 390 million people) fail to 
clear viral replicates resulting in the establishment of chronic infection (Stanaway et. al., 2016). 
Age is a contributing factor and if exposed to HBV within the first year of life, 90% of infants 
progress from acute to chronic infection. The risk decreases if exposure occurs between one and 
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four years of age where approximately 30% of children develop symptoms of chronic disease 
(Stanaway et. al., 2016).  
Chronic HBV infection (CHB) is responsible for around 600 000 deaths annually because of 
an increased risk of infected individuals developing hepatocellular carcinoma (HCC) and 
cirrhosis (Stanaway et. al., 2016). An estimated 25% of CHB patients develop HCC which 
coincides statistically with HBV being responsible for as much as 80% of the worldwide 
occurrence of liver cancers. HBV, therefore, is attributed as being the world’s second most 
important carcinogen after tobacco (Lok & MacMahon, 2009). CHB sufferers coinfected or 
superinfected with the satellite virus Hepatitis D virus (HDV) are at risk of an accelerated 
progression of serious disease consequences because HDV uses HBV envelope proteins for 
dissemination of viral progeny (Rizzetto, 2013). CHB is considered to be a significant challenge 
to the global health status and has been the focus of extensive research initiatives aimed at 
developing control and prevention strategies.  
Acute HBV infection is usually spontaneously resolved by the host’s immune system and 
natural elimination of the virus involves both cellular and humoral immune responses (reviewed 
in: Maini et. al., 2014). HBV infection has an extended incubation period of 6-8 weeks during 
which the virus is undetectable. Clinically, patients will only develop symptoms 10-12 weeks 
post-infection, if symptoms develop at all (Rehermann & Nascimbeni, 2005). Thus, a critical 
phase of initial adaptive and innate immune responses remains incompletely understood because, 
upon diagnosis, the critical window for studying these responses has been lost. Information 
regarding the immune component of initial viral replication has had to be derived in hindsight 
from data generated in chronically-infected patients and animal models of CHB. 
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HBV is a non-cytopathic virus and innate immune responses appear to be very limited during 
the initial phases of infection (Schlomai et. al., 2014; Sato et. al., 2015). In a chimpanzee model 
of acute infection there is no measurable type I IFN response (Wieland et. al., 2004) which 
corroborates observations made in human patients (Dunn et. al., 2009). Two hypotheses exist to 
explain the possible means by which critical innate immune function is undetected in HBV hosts: 
(i) the ‘stealth virus’ hypothesis and (ii) the virus-derived suppression hypothesis. The ‘stealth 
virus’ hypothesis states that HBV can avoid innate immune detection completely. During initial 
phases of replication, cccDNA is confined to the nucleus and viral genomic material is shielded 
by the nucleocapsid within the cytosol hypothetically rendering it unavailable for binding to 
innate pattern recognition receptors (PRRs). Though there is no measurable type I IFN response, 
there is a detectable peak in natural killer (NK) and natural killer T (NKT) cell populations 
preceding the logarithmic phase of replication (Fisicaro et. al., 2009). HBV is, therefore, 
detected by the innate immune system but does not stimulate a typical antiviral response. 
Hypothesis (ii) seems more plausible and HBV-derived proteins have been shown to interfere 
directly with type I IFN production and secretion (Bertoletti & Ferrari, 2011). 
Adaptive immune effector function specific for HBV is likely a crucial element of self-
limiting infection. A population of polyfunctional, HBV-specific T lymphocytes present in the 
pre-logarithmic phase of replication appears to correlate with resolution of infection (Asabe et. 
al., 2009). CD-4+ T cells with HBV-antigen specificity prime CD-8+ T cells and promote their 
survival. CD-8+ T cells can direct non-cytolytic clearance of HBV through the production of 
tumour necrosis factor-α (TNF-α) and IFN-γ. There is a complex interplay between CD-4+ and 
CD-8+ T cells that induces robust TH1 responses. Both cell types play critical roles in affecting 
viral clearance. CD-4+ T-cell depletion studies in chimpanzee models resulted in CD-8+ cell 
27 | P a g e  
 
dysfunction and failure to clear the infectious HBV (Asabe et. al., 2009). At peak viraemia, 
depletion of CD-8+ cells in chimpanzee models eliminated the capacity of the host’s immune 
system to resolve the acute infection (Thimme et. al., 2003). HBV-specific CD-4+ cells can also 
induce humoral immune responses resulting in the production and secretion of anti-HBV 
antibodies by antigen-specific B cells. 
Failure of the host’s immune defenses to clear HBV during acute infection ultimately results 
in viral persistence and the establishment of chronic infection. Chronic HBV infection is 
progressive and patients are found to undergo five distinct phases of disease as summarized by 
Spearman and colleagues in 2013 (Spearman et. al., 2013). In the first phase, or phase of 
immune tolerance, viral replication occurs at high rates, seemingly unhindered by the host 
immune system. During the phase of immune clearance (second phase), viral replication slows 
but the disease complications often increase in severity as a response to elevated levels of 
cytotoxic immune activity within the liver. In patients infected in adulthood, HBeAg 
seroconversion during the second phase of chronic infection allowing progression to phase three 
where patients live as inactive carriers of the virus. Instead of HBeAg seroconversion, induced 
changes in the viral genome may result in limited production of HBeAg in which case the patient 
appears to be in phase three but is in fact suffering from HBeAg-negative chronicity, with a 
much higher associated incidence of cirrhosis and HCC. Patients in phase two or phase three are 
at risk of reverting back to active HBV replication. Finally, patients can suffer from occult HBV 
infection (phase 5) in which there is no detectable HBsAg in the serum but HBV genomic DNA 
is still present. 
Some evidence suggests that HBV may play an active role in the suppression of innate and 
adaptive effector functioning to prevent elimination of the virus from the infected host. A 
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suggested mechanism of HBV-induced immune suppression is the attenuation of Toll-like 
receptor (TLR) signalling (Wu et. al., 2009). TLRs are a highly conserved family of PRRs that 
sense pathogen-associated molecular patterns (PAMPs) resulting in a signal transduction cascade 
to increase production of pro-inflammatory cytokines and type I IFNs, and upregulate co-
stimulatory molecules on the surface of innate immune cells (reviewed in: Akira et. al., 2006). 
Studies performed ex vivo in cultured murine hepatocytes of parenchymal and non-parenchymal 
origin (NPCs) revealed that TLR signalling by NPCs was abrogated in the presence of HBV 
virions, HBsAg or HBeAg (Wu et. al., 2009). The HBV-derived proteins were found to 
downregulate nuclear factor К-light-chain-enhancer (NF- КB) of activated B cells and effector 
proteins of the MAPK pathway (Wu et. al., 2009), both downstream signalling molecules of 
TLR activation.  
The retinoic-acid inducible gene-I (RIG-I)/melanoma differentiation-associated protein 5 
(MDA5) signalling axis permits the cytosolic detection of viral RNA and subsequent innate 
immune activation. HBsAg and HBeAg (Wu et. al., 2009) as well as HBV polymerase inhibit 
interferon regulatory factor-3 (IRF3) activation disrupting the RIG-I signal transduction cascade 
in murine or primary human hepatocytes (PHH) respectively (Yu et. al., 2010). A recent study 
provided evidence that HBV may have a direct inhibitory effect on the production and function 
of IFN-α (Lütgehetmann et. al., 2011) which may explain the poor effectivity of IFN-α treatment 
in many CHB sufferers. The evidence generated to explain the suppression of innate immune 
function during progression to CHB is compelling; however, the data are derived from artificial 
models of infection and remain to be validated in situ. Lack of availability of an appropriate 
animal model of HBV immunopathology renders many conclusions made on the progression of 
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HBV infection to a chronic state theoretical, but a direct inhibitory role of HBV-derived proteins 
on innate immune function would seem plausible.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Suppression of HBV-specific immunity in the chronically-infected liver. CHB patients 
are unable to resolve HBV infection partially because of a tolerogenic hepatic milieu and 
because of an exhausted T-cell phenotype. Unabated antigen exposure with the absence of 
appropriate activating secondary signals causes T-cell anergy. NK cells can deplete HBV-
specific T-cell populations through activation of apoptotic pathways. HBV can suppress T-cell 
functioning by upregulating the expression of the co-inhibitory signalling molecules on the cell 
surface resulting in their suppression rather than activation when encountering MHC-II restricted 
HBV-derived peptides. Chronic HBV infection results in the upregulated production of 
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immunosuppressive cytokines IL10 and TGF-β to promote immune tolerance rather than 
activation. Though incompletely understood, there may be a role for the induction of Tregs in the 
establishment and maintenance of chronic HBV infection.  Image has been adapted with 
permission from: Lamb, C. and Arbuthnot, P., 2016. Activating the innate immune response to 
counter chronic hepatitis B virus infection. Expert Opinion on Biological Therapy, 16(12), 
pp.1517-1527. 
 
1.2.2 Immunological Milieu of the Chronically-Infected Liver  
 
Resolution of acute HBV infection requires robust cellular and humoral immune responses in 
which CD-4+ and CD-8+ cells play critical roles in the elimination of viral particles and infected 
hepatocytes (Guidotti et. al., 2015). CHB induces a tolerogenic hepatic microenvironment 
characteristic of an exhausted T-cell phenotype (Isogawa et. al., 2013). Following resolution of 
acute infection, CD-8+ T cells form populations of highly functional, memory T cells with 
properties that distinguish them from their antigen-naïve, memory-like T cell counterparts. 
Properties of memory CD-8+ T cells include (i) rapid re-activation upon antigen re-encounter, 
(ii) high proliferative potential upon re-activation, (iii) homing to secondary lymphoid tissues 
and (iv) prolonged persistence through the homeostatic maintenance of population numbers by 
interleukin 7 (IL-7)- and IL-15-driven proliferation (Virgin et. al., 2009).  
In CHB, high viral replication rates and unabated antigen exposure results in an exhausted 
CD-8+ T cell phenotype characterised by the loss of IFN-γ production in response to antigenic 
stimulation (Guidotti et. al., 2015) (Figure 3; Lamb & Arbuthnot, 2016). Exhausted memory CD-
8+ T cells no longer produce IL-2, lose their high proliferative capacity and lose their killing 
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capacity during early stages of the conversion to the exhausted phenotype (Wherry, 2011). As 
the cells become more dysfunctional they lose the ability to produce TNF-α and severe 
exhaustion results in complete loss of IFN-γ production and cytotoxic functioning. The terminal 
stage of T-cell exhaustion is the physical loss of existing antigen-specific T-cell populations. 
CD-4+ T cell populations are also affected during chronic viral infection (Brooks et. al., 2005) 
albeit that this process is far less well understood than the effect of chronic infection on CD-8+ 
cells. It is likely that CD-4 cell dysfunction can result in decreased IL-21R production, a 
cytokine that helps maintain antiviral CD-8+ populations (Fröhlich et. al., 2009) implying a 
synergistic loss of adaptive immune control. Elevated IL-10 levels may also be explained by CD-
4+ T cell dysfunction (Brooks et. al., 2006). The more exact role of dysfunctional CD-4+ T cells 
on the mediation of CD-8+ T cell effector function and viral persistence remains an important 
topic of investigation. 
In CHB specifically, several viral and host-derived factors contribute to the establishment of 
exhausted HBV-specific T cells and diminished anti-HBV immunity. Constant exposure to 
HBsAg, HBcAg and HBeAg without the appropriate secondary signals for T-cell activation may 
cause T-cell anergy in CHB patients (Reignat et. al., 2002; Chen et. al., 2005). Elevated levels of 
IL-10 and transforming growth factor-beta (TGF-β) in the chronically-infected liver promote 
tolerance rather than immune activation against HBV. Upregulation of the inhibitory programed 
death protein 1 (PD-1) on hepatocytes, increased production of cytotoxic T-lymphocyte antigen 
4 (CTLA-4), T-cell immunoglobulin and mucin domain 3 (TIM-3), all act to supress immune 
activity and also promote tolerance (Peppa et. al., 2010; Guidotti et. al., 2015). Furthermore, 
IFN-γ-deficient NK cells and regulatory T cells (Tregs) all contribute to a loss of CD-8+ T-cell 
responsiveness to HBV antigens (Isogawa et. al., 2013) (Figure 3). Strategies to restore proper 
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immune function in CHB using immunotherapeutic agents have become a popular avenue of 
investigation for HBV therapy development. Many advances have been made in the attempt to 
reactivate innate immune functioning to augment protective and therapeutic adaptive immune 
responses (reviewed in: Lamb & Arbuthnot, 2016). 
 
1.2.3 Current HBV Immunotherapy 
 
Therapy options available to CHB sufferers are limited in effectiveness and often fail to 
eliminate HBV-infection. These treatments do not prevent but rather prolong the eventual onset 
of severe liver disease complications. First line therapies include treatment with one of five 
clinically approved nucleoside or nucleotide (NUC) analogues which inhibit activity of the HBV 
polymerase; alternatively, patients receive a 48-week course of PEGylated interferon-alpha 
(IFN-α) (Pol & Lampertico, 2012). IFN-based therapeutic strategies have been applied in an 
attempt to reactivate immune effector functions within the microenvironment of the chronically 
infected liver. These strategies are found to be effective in only a small percentage of patients 
and flares in liver disease upon cessation of the therapy occur commonly. IFN-based therapies 
remain relatively ineffective even when administered in combination with NUC analogues and 
are accompanied by significant cost and risk of severe side-effects (reviewed in: Rehermann & 
Bertoletti, 2015). First line therapies are able to supress viral load as monitored by anti-HBsAg 
seroconversion, and in doing so reduce the risk of complicating disease (Hosaka et. al., 2013). 
However, seroconversion alone is not indicative of curative therapy. Disease resurgence is 
common and is likely to occur because of the persistence of cccDNA in infected hepatocytes 
during non-replicative phases of infection (Zoulim & Locarnini, 2009). 
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The field of anti-HBV therapy development is extensive and covers a broad range of 
therapeutic strategies including gene therapy. The use of RNA interference technology (RNAi) 
(reviewed in: Ivacik et. al., 2011) or gene editing technologies such as TALENs (transcription 
activator-like effector nucleases) (Bloom et. al., 2013) to disrupt viral gene expression and 
degrade viral genomic material respectively have become popular means of HBV genome 
silencing. Other strategies involve immunotherapy and the activation of immune responses 
(innate and adaptive) with the goal of eliminating HBV from an infected patient. The use of 
exogenous activators of the innate immune system has gained popularity in recent years as well 
as the possibility for therapeutic vaccination against HBV. 
An ideal anti-HBV immunotherapy would ensure the synergistic actions of the innate and 
adaptive arms of the immune system to eradicate cccDNA and prevent de novo infection of 
hepatocytes by circulating viral particles. Curative therapy would result in (i) seroclearance, (ii) 
durable antiviral effect eliminating the need for life-long, chronic medication, (iii) restoration of 
liver health and function as measured by the normalization of liver markers (eg. serum alanine 
aminotransferase (ALT)) and (iv) no risk of disease resurgence post-treatment. Novel 
immunotherapeutics, and potentially therapeutic vaccination strategies, are necessary and should 
be developed with these goals as key focal points.  
Delivery of recombinant, exogenous immune-activating cytokines and chemokines would 
seem to be a relatively easy way to replace those immunogenic molecules absent in the 
immunological milieu of chronic HBV infection. Though TNF-α and IFN-γ are critical cytokines 
for non-cytolytic control of HBV replication, the administration of cytokines to patients could 
result in lethal systemic inflammatory responses severely limiting their clinical application 
(Guidotti et. al., 1994; McClary et. al., 2000). IFN-α exerts its effects by destabilizing cccDNA 
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(Belloni et. al., 2012; Lucifora et. al., 2014), mediating the innate immune system to activate 
adaptive responses and inhibiting viral gene expression (Rang et. al., 1999; Wieland et. al., 2000; 
Pasquetto et. al., 2002). IFN-α has been approved for human use and has been extensively 
evaluated as a possible immunotherapeutic. Patient data suggest that IFN-α is curative in only a 
very small number of patients and the potential for dangerous side-effects from high doses is 
substantial (Perrillo, 2005). 
Despite the challenges faced when developing novel immunotherapeutics for HBV, the idea 
that activators of the innate arm of the immune system may be curative is encouraging. Artificial 
agonists of TLR7 and 8 have shown great promise as novel therapies. A small molecule, 
GS9620, developed by Gilead Sciences is an orally administered TLR7 agonist which stimulates 
the production of IFN-α by plasmacytoid dendritic cells (pDCs) (Lanford et. al., 2013). By 
stimulating in situ IFN-α production, the cytokine levels are under the control of endogenous 
regulatory mechanisms (reviewed in: Swiecki & Colonna, 2015) and are therefore unlikely to 
reach levels that are harmful to the recipient. Activated pDCs provide the nexus for the innate 
and adaptive arms of the immune system. Activated pDCs can then activate NK cells and CD-8+ 
cells by antigen cross-presentation (Figure 4a). In mice and cynomolgus monkeys, GS9620 
upregulated the expression of interferon stimulated genes (ISGs) and promoted a type I IFN 
response (Fosdick et.al., 2014). In humans, GS9620 elevated levels of IFN-gamma-induced 
protein 10 (IP-10) localised to the liver (Gane et. al., 2015). Short term administration to 
chimpanzees (Lanford et. al., 2013; Fosdick et. al., 2014) and woodchucks (Menne et. al., 2015) 
correlated with suppression of HBV (or Woodchuck Hepatitis Virus, WHV) replication markers, 
reduction of cccDNA and viral mRNA. Also noted was a marked decrease in the risk of 
developing HCC indicating great therapeutic potential in humans. However, chimpanzees and 
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woodchucks were administered low dosages when compared with those needed for efficacy in 
human patients, which may result in unforeseen side effects during clinical testing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Hypothetical mechanisms of action for HBV immunotherapeutic compounds. A) IFN-
α and LTβR agonists. IFN-α activates APOBEC3A and BS1 or CBE11 activates APOBEC3A 
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expression. APOBEC proteins bind HBcAg and are directed to cccDNA where they deaminate 
cytidine nucleotides resulting in the generation of apyrinic/apyrimidinic (AP) sites. AP nucleases 
act at AP sites to cause specific, non-cytolytic degradation of the HBV replication template. B) 
TLR7/8 agonists. Agonists of TLR7/8, for example GS9620, activate pDCs and induce localised 
production of IFN-α. IFN-α activates NK cells which induce CTL effector functioning in CD-8+ 
T-cells. HBV-specific CTL responses are mediated by antigen cross-presentation to HBV-
specific CD8+ T-cells by activated pDCs. The pDCs provide a nexus for the innate and adaptive 
arms of the immune system to overcome HBV-induced immune tolerance and eradicate 
cccDNA-containing hepatocytes. Adapted with permission from: Lamb, C. and Arbuthnot, P., 
2016. Activating the innate immune response to counter chronic hepatitis B virus 
infection. Expert Opinion on Biological Therapy, 16(12), pp.1517-1527.  
 
 
Activation of IFN pathways as an alternative to administering recombinant IFN shows great 
therapeutic promise as indicated by the results from evaluating efficacy of GS9620. Another 
activator of innate anti-HBV effect through IFN mechanisms is STING (Burdette & Vance, 
2013). STING is activated by cyclic dinucleotides that form an integral part of the bacterial 
signal transduction cascade. STING acts as an adaptor molecule for PRRs that are activated by 
DNA detected in the cytosol of infected cells. A STING agonist, 5,6-dimethylxanthenone-4-
acetic acid (DMXAA), has been assessed as an HBV therapy (Guo et. al., 2015) because STING 
activation results in the production of IFN amongst other important cytokines. After 
intraperitoneal administration in murine models, DMXAA induced a robust type I IFN response 
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that was effective in reducing HBV replication. The compound remains to be assessed further 
but thus far the results are promising. 
The formation and persistence of cccDNA is critical in the establishment of CHB in humans. 
Removal of cccDNA either through the destruction of cccDNA itself or through the removal of 
cccDNA-containing hepatocytes would be considered a curative therapy and is the ultimate goal 
of all novel therapeutic development. Recently, Lucifora and colleagues were able to 
demonstrate that stimulation of the IFN pathways could cause direct, nontoxic degradation of 
cccDNA in infected hepatocytes by activating the lymphotoxin β receptor (LTβR) (Lucifora et. 
al., 2014). Tetravalent bispecific (BS1) and bivalent (CBE11) agonistic anti-LTβR antibodies 
stimulated the APOBEC3B-mediated degradation of cccDNA. APOBEC proteins bind HBcAg 
and target deaminating enzymes to the nuclear cccDNA (Figure 4a). In experimental conditions, 
the process was limited to cccDNA and was not found to cause cellular DNA damage, but 
whether or not this would be true if administered in vivo or in CHB patients remains to be 
evaluated. The field of immunotherapy development is very active and there are many examples 
of novel immunotherapeutics in varying stages of development. Here we draw specific attention 
to the prospect of combined therapeutic and prophylactic vaccination as a means of initiating 
protective antibody responses concurrently with re-activating exhausted CD-8+ T cell anti-HBV 
responsiveness. 
 
1.2.4 Prophylactic and Therapeutic Anti-HBV Vaccination 
 
The fortuitous discovery of HBsAg demarcated the first known infection marker of HBV and 
its discovery led to the development of a highly sensitive immunoassay, the HBsAg ELISA, used 
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routinely for diagnosis of infection (reviewed in: Gerlich, 2013). The inherent immunogenicity 
of HBsAg has since supported the development of the first recombinant antiviral vaccine in 
human history. HBsAg produced recombinantly in yeast (Barbacid et. al., 1982) was 
incorporated into a commercially available vaccine in 1982 and currently forms part of globally-
implemented vaccination regimen.  
To date, anti-HBV vaccination is carried out in over 180 countries worldwide and has been 
accredited with reducing global chronic carrier rates by 70-90% (reviewed in: Gerlich, 2014). 
Despite significant success in early childhood and neonate immunization, the effectiveness of the 
recombinant vaccine in adult populations is suboptimal. Even following multiple administration 
attempts, between 2.5 and 5% of healthy adult recipients remain as non- or hyporesponders (with 
no detectable levels or no protective levels of anti-HBsAg antibodies respectively), which 
increases by 5-10% for every decade past 30 years of age. Non-responsiveness is exacerbated in 
circumstances of immunosuppression such as in overweight and diabetic individuals, transplant 
recipients and patients on dialysis as well as people co-infected with HIV (reviewed in Kubba et. 
al., 2003). A large proportion of the adult population, therefore, remains vulnerable to infection 
rendering the goal of HBV eradication unlikely within the paradigm of the current vaccination 
regimen. 
First-generation HBV vaccines were derived from the plasma of chronic HBV carriers; 
Hepatitis B surface antigen (HBsAg) was purified from donated plasma, concentrated and treated 
to eliminate residual infectivity. Administration of the vaccine was associated with a decrease in 
the incidence of new infection within high-risk cohorts (Maupus et. al., 1978; Szmuness et.al., 
1980). However, significant safety concerns regarding the retention of infectivity despite 
treatment, or the potential for accidental transmission of other infectious agents (for example 
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HIV), greatly limited the application. Over the same period of first-generation vaccine 
development, researchers in the field were avidly exploring a means by which to apply 
recombinant DNA technology to the production of HBsAg. Successful attempts were made by 
artificially expressing the S gene of the HBV genome in transformed yeast cultures, providing 
the basis for the second-generation HBV vaccine (Valenzuela et. al., 1982) which was approved 
for commercial distribution in 1982. 
The recombinant HBsAg vaccine currently in global use contains only the SHBs isoform 
and lacks any pre-S epitopes. PreS-containing HBsAg is difficult to produce recombinantly in 
yeast as the protein product is cytotoxic and therefore subjected to intracellular proteolytic 
degradation (Imamura et. al., 1987). Yeast-derived envelope proteins are not processed via the 
secretory pathway and so, as well as lacking the pre-S epitopes, the HBsAg recombinant proteins 
do not become glycosylated (Imamura et. al., 1987). Structural differences between the 
recombinant HBsAg and the native protein have notable effects on the production of 
conformational anti-HBs antibodies and subsequent immunogenicity. 
Evidence suggests that LHBs expressed and processed in transfected mammalian cells 
confer enhanced immunogenicity when compared with conventional recombinant SHBs 
(Heerman et. al., 1987). PreS1/preS2/S protein in the native fold constitutes the group- and 
subtype-specific antigenic determinants. Therefore, anti-preS1 humoral immune responses have 
the potential to produce cross-specific, broadly neutralizing antibodies. Immunization with 
preS1/preS2/S recombinant protein was found to restore full responsiveness in hyporesponders 
or non-responders to the conventional vaccine (Milich et. al., 1985). Sci-B-Vac
TM
, a mammalian 
cell-derived recombinant preS1/preS2/S vaccine (reviewed in: Shouval et. al., 2015) has proven 
efficacy in special risk circumstances and has an enhanced immunogenicity when compared with 
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the standard SHBs recombinant vaccine. The development of a vaccine containing the preS 
regions of HBsAg is justifiable as a method by which to further optimise the prophylactic 
effectiveness of the current vaccine. 
Mammalian cell-based production processes are not desirable as they are costly and 
laborious. This provided a rationale for the development of a third-generation, DNA vaccination 
strategy for the in vivo expression of antigenic gene products. DNA vaccination with synthetic 
plasmid DNA (pDNA) encoding viral antigens is an attractive antiviral approach as DNA 
vaccines have been demonstrated to be capable of inducing cell-mediated and humoral immune 
responses in small animal models, nonhuman primates and human patients (Mallilankaraman et. 
al., 2011; Belisle et. al., 2011; Bagarazzi et. al., 2012). Endogenous antigens expressed from 
delivered gene cassettes are capable of being processed by the cells to induce major 
histocompatibility class I (MHCI) restricted cytotoxic T lymphocyte activation resulting in a TH1 
response and cellular immunity (Figure 5). If targeted to professional antigen presenting cells 
(APCs), endogenous antigens are processed by the MHCII-restriction pathway to induce robust 
antibody responses (Figure 5). In situ antigen production from nucleic acid vaccine constructs, 
therefore, has the dual benefit of prophylaxis and immunotherapy.  
Anti-HBV DNA vaccination strategies have been in development since the 90’s (Davis 
et. al., 1996) and interestingly, anti-HBV DNA vaccination was the first of its kind to have 
demonstrable efficacy in humans (Rottinghaus et. al., 2003). In 2013, Obeng-Adjei and 
colleagues developed a DNA-based multivalent vaccine cocktail from which either LHBs or 
SHBs was expressed concurrently with HBcAg in mice and rhesus macaques (Obeng-Adjei et. 
al., 2013). The antigen-coding sequences delivered intramuscularly as naked pDNA elicited anti-
HBV antibody production directed against multiple epitopes within the S and preS regions. Also, 
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antigen-specific CTL responses were observed by IFN-γ ELISPOT assay and intracellular 
cytokine staining.  The results of the 2013 study are compelling evidence in support of DNA 
vaccination but delivery of naked pDNA in human patients is unfeasible. Naked pDNA will 
activate PRR-mediated innate immunity directed against the vaccine inoculum rather than the 
expressed antigens with potentially harmful consequences. Delivery of DNA vaccines is a 
limiting factor of the technology and DNA therapies are most efficiently delivered by viral 
vectors, the application of which is accompanied by additional and extensive safety concerns. 
Another anti-HBV DNA vaccine cocktail developed by Kim and colleagues in 2008 (Kim et. al., 
2008), HB-110, is currently in the early stages of clinical trials (phase I) in South Korea. 
In vivo expression of multiple HBV gene products stimulated multi-specific Th1 (T-
helper one) and Th2 (T-helper two) immune function supporting the observation that DNA 
vaccines are associated with a cytotoxic T lymphocyte (CTL) response not previously noted for 
subunit or recombinant vaccines (Davis et. al., 1995). CTL responses contribute to the 
recognition and elimination of infected hepatocytes in chronic HBV sufferers or carriers with the 
effect of terminating viral persistence. A nucleic acid vaccination approach, therefore, has 
potential for both prophylactic and immunotherapeutic benefit. Remarkably, repeated 
vaccination with DNA encoding preS1/preS2/S proteins, Hepatitis B core antigen (HBcAg), 
Polymerase (Pol), HBx and an interleukin (IL)-12 adjuvant elicited potent anti-HBV humoral 
and cell-mediated immunity (Yang et. al., 2006). Obtaining maximal effect from in situ encoded 
antigens requires specific delivery to APCs, unachievable by electroporation. Targeting of the 
DNA vaccine to DC-cells using recombinant protein significantly improves the immunogenic 
effect of the vaccine (Wang et. al., 2016) and reduces the risk of aberrant immune stimulation in 
non-target tissues. 
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Therapeutic vaccination would encompass a means by which a vaccination inoculum 
could induce both cellular and humoral immunity with direct antiviral effect. Proof of this 
concept derives from repeated (monthly) Sci-B-Vac
TM
 injections co-administered with daily oral 
lamivudine doses to sufferers of persistent HBV infection (reviewed in: Shouval et. al., 2015). 
The therapeutic campaign supressed viral replication and prompted HBsAg seroconversion in 
~50% of recipients. It is thought that the strategy was sufficient in overcoming T cell exhaustion 
and breaking HBV immune tolerance but the facts remain to be fully elucidated in experimental 
settings. Vaccination of patients with chronic hepatitis C virus (HCV) using pseudo-typed 
chimpanzee adenoviral vectors encoding non-structural HCV proteins successfully induced 
robust and potent anti-HCV T cell responses (Kelly et. al., 2011). DNA vaccination, therefore, 
has an established potential for the treatment of hepatotropic viral infections. The prospect of 
therapeutic DNA-based vaccine technology specific to HBV has gained popularity in recent 
years though there remains some hesitancy regarding the safety profile of therapeutic DNA 
administration.  
 
1.2.5 A Novel Approach: mRNA-based Anti-HBV Vaccination 
 
Apart from difficulties involving the optimal and successful delivery of DNA sequences 
to targeted tissues, DNA vaccine studies often yield conflicting and highly variable efficacy data. 
Consideration of the variability of results stemming from DNA vaccination studies, combined 
with pre-existing safety concerns surrounding the application of DNA therapies in human 
patients, the application of DNA-based vaccination strategies for HBV remains in its infancy. It 
seems unlikely that DNA vaccines will be immediately favoured over other immunotherapies 
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currently in development, whether used alone or in combination with classical NUC analogue 
treatment (Yoon et. al., 2015). mRNA-based vaccination is a method by which to elicit potent 
antigen-specific humoral and cell-mediated immune responses with a superior safety profile 
when compared with DNA vaccines.  
There are additional, distinct features of mRNA that support its preferential use as a 
source of immunogen for vaccination: (i) mRNA has a relatively short intracellular half-life and 
is therefore transiently expressed rendering the bioavailability of the antigenic product 
controllable and predictable, (ii) mRNA translation is carried out in the cytosol and nuclear 
targeting is not necessary reducing the complexity of the delivery method when compared with 
DNA and (iii) there is no possibility for exogenous mRNA to alter the genetic material of the 
hose cell. The ultimate goal of mRNA vaccination is that the antigen will be taken up, expressed 
and processed by APCs in vivo succeeded by the priming of CD8+ and CD4+ T-cell responses. 
However, the majority of mRNA constructs will be taken up by non-immune cells and the 
antigen, therefore, will need to be readily secreted in order to be retaken up and processed by 
APCs to the effect of eliciting humoral immune responses (Figure 5). 
Antigen-encoding mRNA for the induction of CTL immune responses was first evaluated 
for its application as a cancer immunotherapy or for the potential treatment of HIV (Boudreau et. 
al., 2011; Vanham & Van Gulck, 2012). Originally, mRNA immunotherapy was performed by 
isolating DCs from an infected individual and engineering them ex vivo with the mRNA 
construct before reintroduction. Though clinically feasible and safe, engineering DCs ex vivo is a 
complex and costly form of personalised medicine which greatly limits its application within the 
general population. In an HBV-specific context, the regions in which HBV infection is endemic 
are often economically challenged, developing countries without the necessary resources for 
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providing personalised medicine to the afflicted population. Recent advances in non-viral 
nanotechnology facilitates in vivo RNA delivery while at the same time improving mRNA 
stability and enhancing endolysosomal escape upon cell entry (Schlegel et.al., 2013). 
Furthermore, particulate matter is actively phagocytosed by APCs and, combined with some 
chemical modification, could result in better APC-targeting. The application of a lipoplex 
delivery method will be incorporated into the design of the technology here described at a later 
stage of development. 
 
1.3 Rational Design of the mRNA Transcripts for Vaccination  
 
Application of mRNA as a therapeutic alternative to DNA was first described by 
Jirikowski and Sanna in 1992 (Jirikowski & Sanna, 1992). Their approach was largely based on 
an observation made in a seminal article published by Wolff and colleagues (Wolff et. al., 1990) 
a few years before wherein injection of exogenous nucleic acid into murine muscle was capable 
of producing functional protein. Despite a propensity for degradation by abundant nucleases in 
vivo, unprotected pDNA and even mRNA, known to be particularly susceptible to extracellular 
nucleolytic degradation (Probst et. al., 2006), penetrated the cytosol and nucleus. Exogenous 
nucleic acid was processed by cellular mechanisms with the final result being the production of 
the encoded protein localised to the injection site (Wolff et. al., 1990). Specific production of 
antigenic protein from exogenous DNA (Ulmer et. al., 1993) was closely followed by the first 
reported application of mRNA in a vaccine-type formulation (Conry et. al., 1993). However, 
unmodified naked mRNA is highly immunogenic and is capable of inducing undesirable 
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inflammatory responses in recipients limiting its application for human therapies (Kariko et. al., 
2005).  
 The 5’ triphosphate and unmodified bases of exogenous RNA activates a myriad of 
innate immune receptors including but not limited to TLR-3/7/8 and RIG-I. It is likely that inter- 
and intrastrand secondary structural elements of synthetic mRNA mediates activation of RNA-
dependent protein kinases (PKR) (Bevilacqua et. al., 1998). PKR recognises the double-stranded 
RNA genomes of infiltrating viruses during natural infection and becomes activated by 
autophosphorylation. In turn, activated PKR phosphorylates the α-subunit of translation initiation 
factor 2 (eIF-2α) thereby suppressing translation (Hunt & Ehrenfeld, 1971; Ehrenfeld & Hunt, 
1971). Base modifications in endogenous mRNA are common and represent a discriminatory 
molecular feature of endogenous mRNA versus RNA derived from invading pathogens or 
viruses. Some viruses, such as the Herpes Simplex virus, will increase the frequency of base 
modifications as a means of immune evasion (Bokar & Rottman, 1998). The inclusion of 
chemically-modified nucleosides, most commonly pseudouridine, is found to promote evasion of 
PKR recognition (Anderson et. al., 2010) and enhance translational capacity of synthetic mRNA 
(Kariko et. al., 2008). Optimisation of synthetic mRNA with the incorporation of chemically-
modified ribonucleotide bases does not affect delivery efficiency (Anderson et. al., 2010) and is 
indistinguishable from the unmodified counterpart by agarose gel electrophoresis (Kariko et. al., 
2005). 
 Pseudouridine is the most common modified nucleoside in mRNA and is produced from 
the isomerisation of uridine. Inclusion of pseudouridine promotes base stacking and in doing so 
stabilises the duplex regions (Davis, 1995). In rabbit reticulocytes transiently transfected with 
pseudouridine-modified mRNA, protein production from the modified mRNA was 10-fold 
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greater than for the unmodified counterpart (Kariko et. al., 2008). The improved translational 
capacity could be accredited to the enhanced stability and decreased immunogenicity of the 
mRNA which in turn extends the half-life of the synthetic transcripts. Interestingly, it is a topic 
of debate as to whether base modification is useful for mRNA vaccine design where the intrinsic 
adjuvanticity of the mRNA could prove beneficial. Inclusion of pseudouridine suppresses the 
induction of TNF-α and IL12 secretion from monocyte-derived DCs by reducing the production 
of IFN-γ (Kariko et. al., 2008). TNF-α and IL12 enhance CTL and NK responses, and APCs 
polarise T-cell responses in an IL12-dependent manner (Koski et. al., 2004). IFN-γ acts as the 
priming signal to maximise IL12 secretion by maturing DCs and immunogenic RNA substitutes 
this signal. It is logical, therefore, that pseudouridine-modified mRNA in a vaccine formulation 
could actually limit vaccine efficacy.  
 A means of circumventing the inclusion of modified bases without resulting in 
suboptimal translational capacity of the mRNA is by sequence-engineering the mRNA 
production constructs. Such an approach is the focus of the current study and has been applied 
during the design process. Sequence-engineering of mRNA occurs in two ways: (i) sequence 
optimisation by considering adapted codon usage in different expression organisms and (ii) 
selection of appropriate regulatory sequences (UTRs) (Thess et. al., 2015). These approaches 
have proven efficient in attaining protein production levels comparable to the non-engineered, 
chemically modified transcripts (Thess et. al., 2015). In the current study, the gene of interest 
was processed using a codon-optimisation algorithm to produce a sequence adapted for optimal 
translation in humans as the primary and mice as the secondary organisms of expression. The 
mRNA here produced includes the 5’ UTR of the β-globin gene and 3’ UTR of α-globin which 
encompasses pyrimidine-rich sequences that act to stabilise the mRNA by binding the ubiquitous 
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α-complex of eIF2 (reviewed in: Pascolo, 2008). Sequence-engineering of the synthetic mRNA 
is a critical aspect of the current study and has been applied here in an attempt to ensure optimal 
applicability of the mRNA in a vaccine formulation at a later stage.  
 Additional aspects are included in the design of the mRNA production process to ensure 
optimal translation of the transcripts: (i) incorporation of a Kozak sequence (Kozak, 1978) in the 
5’UTR that overlaps the start codon to optimise translation, (ii) 5’-capping of the transcripts 
concurrently with transcription using an anti-reverse cap analogue (ARCA) and (iii) the 
incorporation of a poly (A) tail mimic by transcription of the poly T:A sequence stretch (~95nt) 
downstream 3’UTR. By these methods, the synthetic mRNA will structurally mimic endogenous 
transcripts. ARCA will be incorporated concurrently with nascent bases which will ensure that 
~80% of the transcripts will be in the correct orientation for productive translation. ARCA-
capped mRNA has a two-fold greater translational efficiency than uncapped mRNA in rabbit 
reticulocytes (Stepinski et. al., 2001) possibly because it has a longer half-life (Grudzein et. al., 
2009) and therefore prolonged protein expression (Zohra et. al., 2007). The ~95nt poly (A) tail 
along with the globin UTRs should function in stabilising the synthetic mRNA (Mockey et. al., 
2006; Holtkamp et. al., 2006).  
The current study was aimed at the development of an anti-HBV mRNA vaccine for the 
purpose of improved prophylactic potency through the inclusion of all critical HBsAg epitopes 
and as well as exploring the use of mRNA vaccination as a novel immunotherapeutic. This 
dissertation describes the early development and design stages of the mRNA vaccine 
complement in which codon-optimised DNA sequences were successfully subcloned into 
specially engineered mRNA production vectors for downstream in vitro transcription of 
synthetic LHBs and SHBs mRNA. We were able to produce mRNA using this method that was 
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translated into detectable LHBs and SHBs in cultured hepatoma cells in vitro. However, it was 
found that SHBs was readily secreted into the cytoplasm while LHBs remained trapped inside 
the cell, an important fact that will require downstream optimisation to ensure full immunogenic 
benefit of the vaccine when being tested in vivo. Overall, the current study has provided the 
framework for further development of the vaccine and establishment of functionality at a later 
stage of development. 
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Figure 5: Theoretical initiation of humoral and cellular immunity from mRNA vaccine products 
in situ. Lipoplex-associated mRNA is protected from extracellular endonucleases and (1) 
nanoparticle uptake from the extracellular environment is mediated by endocytosis. (2) Within 
the acidic environment of the endolysosome, the acid-base chemistry of the lipoplex delivery 
vehicles directs an increase in overall positive charge to allow for attachment and fusion to the 
anionic, endosomal membrane; the mRNA payload escapes degradation and is released into the 
cytosolic compartment. (3) The mRNA constructs enter the endogenous protein synthesis 
pathway and are translated to produce S-HBsAg or L-HBsAg. (4) mRNA has a relatively short 
half-life and is rapidly degraded by intracellular RNAses upon termination of translation. (5) The 
protein produced is either (6) secreted or (7) degraded in a proteasome-dependent manner; 
peptides from the degraded protein enter the endoplasmic reticulum and become bound to MHC 
class I molecules which are transported to the surface for MHC class I-restricted antigen 
presentation and the induction of CD8+ T-cell responses (9). (8) Re-uptake of the secreted 
protein by endocytosis is followed by endosomal degradation and peptide binding to MHC class 
II molecules which are then transported to the cell surface for MHC class II-restricted antigen 
presentation to CD4+ T-cells (9). Antigenic products of a DNA vaccine would ultimately be 
processed in much the same way with the exception that the DNA would first need to be 
translocated to the nucleus for transcription and the delivery method may differ from the lipoplex 
formation here shown. 
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2. MATERIALS AND METHODS  
 
2.1 Generation of mRNA production templates and in vitro expression vectors  
 
2.1.1 Design of the mRNA production pDNA backbone 
 
To produce synthetic mRNA by T7 transcription in vitro, a suitable mRNA pDNA 
production template was designed to serve as the backbone into which all mRNA-encoding DNA 
sequences were subcloned. T7 transcription is a method whereby the phage T7 polymerase is 
used for high fidelity synthesis of mRNA transcripts under the transcriptional control of the 
promoter specific to the phage protein, the T7 promoter. The mRNA production backbone is 
referred to as pmRNA-MCS-95A where MCS is the abbreviation for ‘multiple cloning site’. The 
pmRNA-MCS-95A backbone was designed to contain (in a 5’ to 3’ direction) (i) a M13 forward 
(M13F) sequencing primer-binding site (not shown), (ii) a T7 promoter, (iii) the 5’ untranslated 
region (UTR) of the rapine β-globin gene (iv) followed immediately downstream by the MCS, 
(v) the 3’ UTR of the murine α-globin gene, (vi) a stretch of 95 thymidine residues on the coding 
strand (poly A:T), followed further downstream by the (vii) M13 reverse (M13R) sequencing 
primer-binding site (not shown) (Figure 6).   
The sequences M13F, T7, α-globin 5’UTR, β-globin 3’UTR and M13R are standard 
sequences and were obtained from GenBank
® 
NIH genetic sequence database (available at: 
https://www.ncbi.nlm.nih.gov/genbank/). Within the 5’ UTR is the Kozak consensus core 
sequence, (gcc)gccRccAUGG (Kozak, 1978), included to optimise translation of the mRNA 
(appendix A1-1). The MCS sequence was pieced together using known, overlapping Type II 
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restriction endonuclease binding sites (Appendix A1-1). The MCS ensured that the plasmid 
template is amenable to other subcloning experiments to be performed at a later stage if needed. 
The stretch of sequences between the M13F and the T7 promoter, as well as from the 3’ terminus 
of the poly (T) sequence to the M13R were abstracted from the standard pUC57 backbone. 
Downstream of the poly A:T sequence, a HindIII restriction site was included for use in the 
linearization step of the mRNA production protocol (Section 2.3).  
The sequences were pieced together in FASTA format and sent to GenScript
®
 for 
synthesis using the GenPlus
TM
 High-throughput Gene Synthesis next-generation gene synthesis 
technology platform. The synthesized genetic fragment was subcloned by GenScript
® 
into a 
pUC57 backbone and returned to us accompanied by a certificate of analysis and confirmation of 
sequence identity. The plasmid DNA was prepared and purified for downstream application 
using the Qiagen
®
 Plasmid Purification Maxi Kit (appendix A2-1). 
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Figure 6: mRNA Production Template. The mRNA production sequences include a T7 promoter 
which drives in vitro transcription by T7 polymerase, followed by the 5’ UTR of the rapine β-
globin gene and the 3’UTR of the murine α-globin gene punctuated by the MCS. Included in the 
MCS are NcoI and PmeI restriction sites used for subcloning of mRNA-coding sequences. 
Immediately downstream of the 3’UTR is the poly A:T stretch on the coding strand which is 
transcribed into a poly (A) tail mimic during in vitro transcription. Several (~8) nucleotides 
downstream from the 3’ terminus of the poly A:T sequence is a HindIII restriction site used for 
template linearization during mRNA production. 
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2.1.2 Codon-optimisation of the LHBs coding sequence  
 
For the production of sequence-engineered mRNA, a sequence codon-optimisation 
approach for the HBsAg-coding sequence was adopted. Different species have adapted codon-
usage and codon optimisation is a way to improve translatability of the mRNA. The LHBs 
sequence of HBV Genotype A1, isolate Mart-B27 (Brichler et. al., 2013) was sourced from 
GenBank
® 
NIH genetic sequence database (accession number: HE974370.1). The sequence was 
extracted from the total genomic sequence and saved in FASTA format with a NcoI restriction 
site added at the 5’ end and a PmeI restriction site at the 3’ end, preceded by a guanidine 
dinucleotide sequence (for reconstruction of the complete 3’UTR). Towards the 3’ end of the 
LHBs gene is the SHBs ORF which was extracted by PCR at a later stage (see section 2.1.3.1).  
The FASTA sequence file was sent to GenScript
® 
for synthesis as described above 
(Section 2.1.1).The synthesised gene was codon-optimised by GenScript
®
 using the patented 
OptimumGene
TM 
(Liu et. al., 2012; US Patent 8326547B2) optimisation algorithm with humans 
as the primary, and mice as the secondary organism for expression. The codon-optimised LHBs 
sequence was processed by Genscript and returned as described in section 2.1.1. The pDNA, 
referred to as pUC57-preS1/preS2/S (CO) was prepared and purified for downstream application 
using the Qiagen
®
 Plasmid Purification Maxi Kit (Qiagen, Germany) (appendix A2-1).  
 
2.1.3 Construction of the mRNA production and in vitro expression vectors 
 
Three mRNA production plasmids were generated for the purposes of the current study: 
(i) pmRNA-LHBs-95A, (ii) pmRNA-SHBs-95A and (iii) pmRNA-eGFP-95A. The pmRNA 
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plasmids were modified to include a CMV promoter/enhancer sequence upstream of the T7 
promoter and in frame with the mRNA-coding DNA sequences (Figure 7). A CMV 
promoter/enhancer controls strong expression of downstream DNA sequences in mammalian 
cells and is used commonly in eukaryotic expression vectors. The modified plasmids; (i) 
pmRNA-CMV-LHBs, (ii) pmRNA-CMV-SHBs and (iii) pmRNA-CMV-eGFP (Table 1), could 
therefore be used to assess protein expression from the cloned sequences in vitro prior to mRNA 
production. The pmRNA-eGFP-95A plasmid was included as a control plasmid for protein 
expression from the DNA and from the produced mRNA. An additional control plasmid, 
pmRNA-CMV-MCS, was constructed to be used a mock control plasmid during DNA 
transfection experiments. 
2.1.3.1 PCR amplification of the required sequences   
The LHBs, SHBs, eGFP and CMV promoter/enhancer sequences were amplified from 
various donor plasmids by standard polymerase chain reaction (PCR). The eGFP sequence and 
CMV promoter/enhancer sequences were amplified from pCI-neo-eGFP while both the LHBs 
and SHBs sequences were amplified from pUC57-preS1/preS2/S (CO) (Figure 8). All 
amplification reactions were performed using the KAPA Taq ReadyMix PCR Kit (Kapa 
Biosystems, MA, USA) according to the manufacturer’s instructions. Forward and reverse 
primers for each amplification reaction were synthesised by standard phosphoramidite chemistry 
(Integrated DNA Technologies, IA, USA) and contained no additional modifications. Primer 
sequences as well as specifics of each PCR reaction are described in Table 2. Primers were 
designed to incorporate a 5’ NcoI and 3’ PmeI site to each amplified sequence for subsequent 
subcloning into pmRNA-MCS-95A. Amplification was performed using a T100
TM
 Thermal 
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Cycler (Bio Rad Laboratories, RSA) and the thermal cycler profiles for each reaction are shown 
in appendix A3-1. 
Table 1: List of plasmid constructs and their intended use.  
Description  Plasmid Construct Experimental Application 
Foundational constructs  
pmRNA-MCS-95A Subcloning  
pUC57-preS1/preS2/S (CO) 
Source of codon-optimised LHBs 
and SHBs 
mRNA production vectors 
(premature stage of subcloning ) 
pmRNA-eGFP-95A mRNA production by in vitro 
transcription using T7 phage 
polymerase  
pmRNA-LHBs-95A 
pmRNA-SHBs-95A 
mRNA production and in vitro 
expression vectors  
pmRNA-CMV-MCS Mock control 
pmRNA-CMV-eGFP Transfection efficiency control 
pmRNA-CMV-LHBs 
Expression of LHBs in vitro and 
production of LHBs mRNA 
pmRNA-CMV-SHBs 
Expression of SHBs in vitro and 
production of SHBs mRNA 
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Figure 7: Schematic of critical sequence elements within the pmRNA-CMV plasmid constructs. The plasmids were designed for dual 
experimental purpose: (i) drive protein expression in vitro in cultured cells and (ii) permit in vitro transcription for mRNA synthesis. 
The CMV promoter/enhancer drove transcription of a long mRNA inclusive of all the sequence elements needed for mRNA 
production. Translation of the encoded protein, which was subsequently expressed from the synthetic mRNA transcripts, was initiated 
at the translational start site (within the NcoI recognition and restriction sequence). The design of this vector allowed for pre-
evaluation of protein production before initiating mRNA transcript synthesis from the same plasmid construct. This was particularly 
important for assessment of HBsAg expression from codon-optimised LHBs and SHBs.   
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Figure 8: Generation of cloning fragments by PCR. The eGFP cloning fragment was amplified from pCI-neo-eGFP using the 
FeGFP(Koz) and ReGFP forward and reverse primers respectively. The amplicon was approximately 720bp in length. The CMV 
enhancer/promoter sequence of approximately 600bp was amplified from the same donor plasmid, pCI-neo-eGFP, using the CMV 
Fwd and CMV Rev primer set. LHBs (~1200bp) and SHBs (~680bp) were amplified from pUC57-preS1/preS2/S (CO) using the 
FLH(Koz) and FSH(Koz) forward primers respectively and the same reverse primer, RsORF. 
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Approximately 1 ng of respective pDNA donor template and 20 pmole each of forward 
and reverse primer were included in each amplification reaction. The amplification cycles were 
repeated 35 times in each instance and for each respective PCR, 5 independent reactions were 
set-up and amplicons of the same identity were then pooled for purification. Immediately post-
amplification, 1 μl of each reaction was analysed by gel electrophoresis through a 1% agarose 
gel (120V, 35 minutes) for visualisation (ethidium bromide-staining) of amplicon quality and 
purity. High quality amplicons of the same identities were pooled and purified further using the 
QIAquick PCR Purification Kit (Qiagen, Germany) operated according to the manufacturer’s 
instructions. Purified amplicons were eluted in 30 μl of double-deionised water (ddH2O) and 
quantified using the NanoDrop 1000 (Thermo-Scientific, MA, USA) spectrophotometer. An 
elution check of the purified amplicon was performed by agarose gel electrophoresis (according 
to the conditions described above) loaded with approximately 250 ng of the amplicon eluent. All 
eluents were stored at -20
o
C if not used immediately.   
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Table 2: Specific primer sequences and PCR conditions (restriction sites are underlined).  
Amplicon 
Identity 
Primer Sequences (5’-3’) 
Annealing 
T (
o
C) 
Elongation 
Time 
(minutes) 
eGFP 
Fwd 
FeGFP(Koz): 
TAG CCG CCA CCA TGG TGA GCA AGG 
GCG AG 
50 1:30 
Rev 
ReGFP: 
CAG CGT TTA AAC GGG CCC TTA CTT 
GTA CAG CTC GTC 
CMV  
Fwd 
CMV Fwd: 
CGG CCA GTG AAT TGG CAT TGA TTA 
TTG ACT 
50 1:30 
Rev 
CMV Rev: 
CTA AAC GAG CTC TGC TTA TAT AGA 
CCT CCC 
LHBs 
Fwd 
FLH(Koz): 
TAG CCG CCA CCA TGG GGG GGT GGT 
CAA GC 
55 2:15 
Rev 
RsORF:  
CAG CGT TTA AAC GGG CCC TCA AAT 
GTA GAC CCA CAG 
SHBs 
Fwd 
FSH(Koz): 
TAG CCG CCA CCA TGG AGA ATA TTA 
CTT CC 
50 1:30 
Rev 
RsORF:  
CAG CGT TTA AAC GGG CCC TCA AAT 
GTA GAC CCA CAG 
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2.1.3.2 Amplicon sequence confirmation 
 Purified amplicons were subcloned into linearised pTZ57/R using the InsTAclone
TM
 PCR 
Cloning Kit (Thermo-Scientific, MA, USA). Manufacturer’s instructions for ligation reaction 
set-up were followed exactly using an insert/vector ratio of 1:3. Calculations of vector and insert 
amounts were performed according to the table provided in the manual of the kit (Table A3-2.1). 
The final ligation volume was 30 μl and the ligations reactions were incubated overnight (O/N) 
(~16 hours) at 22
o
C in a refrigerated water bath. Included in the ligation reaction layout was a 
positive control provided by the kit as well as a no-insert control (NIC) wherein only the 
linearised backbone was present in the ligation reaction.  
For the transformation reactions, 50 μl of competent XL10 Gold® E. coli were 
transformed with 2.5 μl of each ligation reaction mix (Appendix A2-2) and plated onto 
ampicillin plates coated with X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside) and 
IPTG (isopropyl thiogalactoside) (Appendix A2-1). The plates were left to incubate upside-down 
O/N at 37
o
C and then individual white colonies from the plates were used to inoculate 20 ml of 
Luria Bertani (LB) medium (Appendix A2, table A2 1.2). The pDNA was extracted and purified 
and included in various restriction digest reactions to screen for positive clones (Table 3). 
Positive clones were sent for standard Sanger sequencing by Inqaba Biotec, RSA. Sequencing 
was performed using M13F and M13R sequencing primers. 
Sequencing data extracted from the chromatograms provided by Inqaba Biotec were 
saved in FASTA format (query sequence). A multiple sequence alignment algorithm, BLASTN 
(available at: https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch), was used to 
align the extracted sequence with the original, desired sequence (subject sequence). Sequences 
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with 100% query identity were considered true positive clones and selected for scaled-up pDNA 
preparation (Appendix A2, Table A2 1.2). 
2.1.3.3 Subcloning of mRNA-coding sequences and CMV promoter/enhancer 
 The mRNA-coding sequences (eGFP, LHBs and SHBs) contained a 5’ NcoI and 3’ PmeI 
site introduced during PCR amplification. The PmeI restriction site in pmRNA-MCS-95A is 2 
nucleotides downstream of the start of the 3’ UTR but this sequence region was reconstituted by 
the reverse primers (Table 2). The strategy employed to construct the final in vitro expression 
vectors involved 2 distinct cloning steps because there is an NcoI restriction site within the CMV 
promoter/enhancer sequence. First, the mRNA-coding sequences excised from the positive pTZ 
clones using NcoI-HF
®
 and PmeI (NEB, MA, USA) were subcloned into complementary sites 
within the linearised pmRNA-MCS-95A backbone (Figure 9). Confirmed positive pmRNA 
clones, and the selected pTZ-CMV, were digested with BstXI and SacI (Thermo-Scientific, MA, 
USA). The CMV promoter/enhancer insert was then subcloned into the relevant sites within the 
linearised pmRNA (with coding insert) backbone to construct the dual in vitro expression and 
mRNA production plasmids (Figure 9). The pmRNA-CMV-MCS mock control plasmid was 
included only in the second stage of the cloning protocol (Table 1). Identical experimental 
proceedings were applied at all stages of subcloning which are described in detail in Appendix 
A3-2. 
 Restriction digestion with NcoI-HF
®
 and PmeI (NEB, MA, USA) was performed as a 
double digestion reaction in CutSmart
TM
 buffer (NEB, MA, USA) within a final reaction volume 
of 50 μl. BstXI and SacI (Thermo-Scientific, MA, USA) have optimal activities in different 
buffer systems and at different temperatures. Two separate digestion reactions were therefore 
performed consecutively, on the same DNA sample, to obtain the necessary fragments. The first 
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stage of the digestion reaction using BstXI was performed in 1× Buffer O (Thermo-Scientific, 
MA, USA) in a total reaction volume of 20 μl. The reaction was incubated at 55oC in a T100TM 
Thermal Cycler (Bio Rad Laboratories, RSA) for 60 minutes. The digested DNA was purified 
from the reaction volume using the QIAquick PCR Purification Kit (Qiagen, Germany) 
according to the kit manual and eluted in 30 μl of ddH2O. A 1 μl volume of eluent was used for 
an elution check (agarose gel electrophoresis). Upon confirmation of successful digestion, the 
remaining volume of eluent was included in the second stage of the restriction digestion reaction 
(Figure 9). The SacI digestion reaction was set up in a final reaction volume of 50 μl which 
included 1× SacI buffer (Thermo-Scientific, MA, USA). The reaction mix was incubated at 37
o
C 
for 60 minutes. The protocol outlined in appendix A3-2 was then completed using the extracted 
inserts and vector backbones. 
 Screening for positive clones for all the generated plasmids was performed by restriction 
mapping with several different enzymes chosen specifically for each plasmid type. The 
restriction enzymes used, as well as the respective reaction conditions for screening final in vitro 
expression and mRNA production plasmids is outlined in Table 3. All restriction enzymes used 
were FastDigest
TM
 enzymes (Thermo-Scientific, MA, USA) and all reactions were incubated at 
37
o
C for 30 minutes.  Digestion reactions were analysed by agarose gel electrophoresis and 
positive clones were selected based on the band sizes of the DNA fragments resulting from each 
digestion. A GeneRuler
TM
 DNA Ladder Mix (Thermo-Scientific, MA, USA) was run alongside 
the samples for size comparison.  
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Figure 9: Overview of the cloning strategy for generating mRNA production and in vitro 
expression vectors. Sequence-checked mRNA-coding inserts were excised from the pTZ clones 
using NcoI and PmeI. The excised inserts were then ligated into specific free ends on the 
pmRNA backbone digested with the same enzymes to create the mRNA production plasmids. 
These plasmids were then included in an additional subcloning step wherein they were digested 
with BstXI and SacI. The CMV promoter/enhancer sequence was extracted from pTZ-CMV 
using BstXI and SacI and ligated into the linearised mRNA production plasmid backbones to 
give the final plasmids which were used for in vitro expression analyses and mRNA production.   
 
 
 
 
Table 3: Restriction digestion: Screening for positive clones. All enzymes shown are 
FastDigest
TM
 enzymes (Thermo-Scientific, MA, USA). The reactions were made up in a final 
volume of 20μl and were incubated at 37o C for 30 minutes. 
 
 
 
 
 
Enzymes  
Buffer 
Screen 1 Screen 2 
pmRNA-CMV-MCS SpeI + ScaI EcoRI + NotI 
1X FastDigest
TM
 
Green Buffer 
pmRNA-CMV-EGFP SpeI + ScaI EcoRI + BamHI 
pmRNA-CMV-LHBs SpeI + ScaI ApaLI 
pmRNA-CMV-SHBs SpeI + ScaI ApaLI 
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2.2 Optimisation of immunofluorescence protocol for the detection of intracellular HBsAg  
 
2.2.1 Antibodies  
 
 For the purposes of the current study, we needed to detect LHBs and SHBs and 
distinguish between the two protein isoforms using immunofluorescence. Three murine 
monoclonal primary antibodies were selected, namely anti-S (S14; ab8636, Abcam
®
, Cambridge, 
UK), anti-preS1 (AP1; sc-5776, Santa Cruz Biotechnologies, TX, USA) and anti-preS2 (S26; sc-
23944, Santa Cruz Biotechnologies, TX, USA). The anti-S antibody detected SHBs, and LHBs 
while the anti-preS1 and anti-preS2 antibodies were specific for LHBs. A goat anti-mouse IgG 
polyclonal secondary antibody conjugated to Alexa Fluor
®
 488 (Thermo-Scientific, MA, USA) 
was used for detection of bound primary antibody. A standard immunofluorescence protocol was 
followed (Appendix A2-3); however, it was necessary to optimise primary antibody incubation 
conditions for optimal detection of intracellular HBsAg. This was because the antibodies have 
not been broadly applied for detection of in vitro intracellular HBsAg protein. Primary antibodies 
AP1 and S14 were used at a dilution of 1:100 and S14 was used diluted 1:50.  
 
2.2.2 Culture of HepG2.2.15 Cells  
 
 HepG2.2.15 cells are G418-resistant derivatives of the HepG2 hepatoblastoma cell line 
which carry four tandem copies of the HBV genome (5’-3’) (Sells et. al., 1987).  Typically, 
HepG2.2.15 cells are used as in vitro replication models for HBV and constitutively produce all 
the HBV-associated proteins including HBsAg. Cultured HepG2.2.15 cells, therefore, allowed 
for optimisation of the immunofluorescence staining protocol prior to DNA or RNA transfection. 
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HepG2.2.15 cells were maintained in Gibco
®
 Dulbecco’s Modified Eagle Medium (DMEM) 
(Life Technologies, CA, USA) supplemented with penicillin (10 000 units/ml), streptomycin 
(100μg/ml) and 10% heat-inactivated fetal calf serum (FCS). Cultures were incubated at 37oC 
and 5% CO2.  
 
2.2.3 Conditions Assessed for Optimisation 
 
HepG2.2.15 cells were seeded in 96 well culture dishes at ~38 000 cells/well (~80% 
confluency) and incubated overnight or until the confluency reached ~90%. Once the cells had 
grown to a sufficient confluency, they were immediately fixed in 4% (w/v) paraformaldehyde 
(PFA), permeabilized in 0.1% (v/v) Triton
TM
-X100 (Sigma-Aldrich, MS, USA) and either used 
immediately or stored at 4
o
C in a humidified chamber (Appendix A2-3). Three incubation 
conditions for the primary antibodies were tested: (i) incubation in primary antibody for 24 hours 
at 4
o
C, (ii) extending the blocking step to 24 hours overnight at 4
o
C or (iii) an in primary 
antibody incubation of 1 hour at RT. All incubation conditions were performed in a humidity 
chamber. The immunofluorescence protocol was completed and the stained cells imaged using 
the Zeiss Axio Imager inverted fluorescence microscope (Zeiss, Germany) and the AxioVision 
(V3.8.1) imaging software. 
 
2.3 In vitro synthesis of mRNA transcripts 
 
The synthesis of mRNA transcripts was completed in two stages: (i) linearisation and 
purification of the pmRNA template and (ii) in vitro T7 transcription using the linearised 
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template (Figure 10). Initially, the pmRNA template was designed to be linearised using a Type 
IIS restriction enzyme, SapI. The recognition site of SapI was just downstream of the poly A:T 
sequence and the restriction site 5 thymidine residues before the 3’ terminus of the poly A:T such 
that the final nucleotide on the linear coding strand was a thymidine. The restriction activity of 
Type IIS enzymes relative to Type II enzymes differs in cleavage efficiency. Often, Type IIS 
enzymes require more than one recognition site to be present to cleave the DNA and the pmRNA 
backbone harboured two SapI sites ~350 bp apart. Incomplete linearisation of plasmid template 
was consistently noted (Appendix A4-1) whereby the DNA was cleaved at only 1 of the 2 sites 
and only a small portion of the DNA was cleaved at both sites. As a result of using pmRNA 
templates of different lengths, mRNA transcripts of differing lengths were produced as an 
impure mixture. Instead, a HindIII site located ~8nt downstream of the 3’ terminus of the poly 
A:T sequence was used because HindIII is a high fidelity, robust restriction enzyme that 
achieved complete linearisation more efficiently. 
Table 4: Reaction set-up for in vitro transcription by T7. mMESSAGE mMACHINE
®
 T7 
ULTRA Kit Reagents are listed in the order of their addition to the reaction mix 
 Positive Control (μl)  Experimental Sample (μl)  
Ambion
®
 Nuclease-free H2O 4 (make volume up to 20μl) 
rNTPs/ARCA 10 10 
10X Reaction Buffer  2 2 
Linear DNA Template  2 (up to 1μg) 
T7  2 2 
 VT 20 20 
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Figure 10: Schematic of mRNA production protocol. Synthesis of mRNA transcripts by in vitro 
T7 transcription was performed in two stages: (i) Linearisation of the DNA template and (ii) 
production of transcripts by in vitro transcription. HindIII was used to linearise the plasmid 
template by cleaving the DNA downstream of the poly (T) sequence on the coding strand. In 
doing so the mRNA transcripts produced in (ii) are of a predetermined length and all transcripts 
produced are identical. Included in the T7 transcription reaction set-up was ARCA (m
7
GpppG) 
which functions as a mimic of a 5’ cap found in endogenous mRNA. The poly A:T sequence was 
converted to a poly (A) sequence in the transcripts which functions in mimicking the poly (A) 
tail found in eukaryotic mRNA. 
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The linearisation reaction was set-up using 10 μg of high quality, high purity pmRNA 
plasmid per reaction. Included in the final reaction volume of 50 μl were 10 U HindIII-HF® and 
1× CutSmart
®
 Buffer (NEB, MA, USA). The reaction volume was made up in ddH2O and mixed 
thoroughly before incubation for 60 minutes at 37
o
C. Immediately post-incubation, 1μl of the 
restriction digest reaction was analysed using agarose gel electrophoresis  to assess complete 
linearisation. If confirmed to be completely linear, the remainder of the restriction digest reaction 
(49 μl) was purified using the QIAquick PCR Purification Kit (Qiagen, Germany) according to 
the manufacturer’s instructions. The linear template was eluted in 30 μl of TE buffer (provided in 
kit) and quantified using the NanoDrop 1000 spectrophotometer. An elution check by agarose 
gel electrophoresis was performed using 1 μl of the eluent. Linearisation was completed on the 
day of, or the day before, the in vitro transcription reaction and no template was stored at -20
o
C 
for more than 24 hours before use.  
T7 in vitro transcription was achieved using the mMESSAGE mMACHINE
®
 T7 Ultra 
Kit (Life Technologies, CA, USA). In brief, the reaction was set up according to table 4 and 
incubated for exactly 2 hours at 37
oC in a thermal cycler. A quantity of 1 μg purified linear DNA 
was used as the transcription template. The reaction set up included the rNTPs in specific ratios 
as well as the anti-reverse cap analogue (ARCA) included to mimic the 5’ cap of endogenous 
eukaryotic mRNA. The final reaction volume of 20 μl was made up in Ambion® nuclease-free 
water (Life Technologies, CA, USA). To eliminate the pmRNA template, 1 μl of TURBO® 
DNAse was added followed by another 15 minute incubation at 37
o
C. 
After incubation, the reaction (20 μl) was thoroughly mixed with 30 μl of ice-cold 7.5 M 
lithium chloride (LiCl) solution (containing 50 mM EDTA) (provided in kit) and incubated at -
20
o
C for 60 minutes to allow for precipitation of the mRNA. The solutions were kept on ice from 
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this point to preserve mRNA integrity. To isolate the mRNA by precipitation the LiCl solutions 
were centrifuged at 12 000 ×g for 15 minutes (4
o
C). The supernatant was carefully removed and 
the mRNA pellet was washed in 1 ml of ice-cold 70% (v/v) ethanol prepared fresh using 
Ambion
®
 nuclease-free water (Life Technologies, CA, USA). The ethanol wash step required 
centrifugation at 12 000 ×g for 15 minutes (4
o
C) following which as much of the ethanol as 
possible was removed by pipette aspiration without disturbing the mRNA pellet. The pellets 
were then subjected to additional centrifugation steps of 1 minute at 12 000 ×g (4
o
C) followed on 
by aspiration of residual ethanol until all of the ethanol had been removed. The pellets were 
resuspended in 10 μl of Ambion® nuclease-free water (Life Technologies, CA, USA) and a 1:10 
dilution was made for quantification by spectrophotometry using the NanoDrop 1000. Once 
quantified, the mRNA was assessed by formaldehyde-agarose gel electrophoresis (appendix A2-
4). Pure, non-degraded mRNA was aliquoted in 2 μg aliquots and stored at -80oC until needed.  
 
2.4 Transfection of Huh7 cells to assess HBsAg expression 
 
The human hepatoma-derived cell line, Huh7 (Nakabayashi et. al., 1982), was maintained 
in Gibco
®
 DMEM (Life Technologies, CA, USA) supplemented with 10% heat-inactivated FCS, 
penicillin (10 000 units/ml) and streptomycin (100 μg/ml). Cells were seeded at ~40% 
confluency (38 000 cells/well) in a 48 well culture dish in antibiotic-free Gibco
®
 DMEM 
supplemented with 10% heat-inactivated FCS. The seeded cells were incubated at 37
o
C and 5% 
CO2 O/N (~20-24 hours) or until reaching ~80% confluency before proceeding with transfection. 
Transfection efficiency was measured by the inclusion of pDNA/mRNA expressed to produce 
eGFP which was then visually assessed using standard fluorescence microscopy on the Zeiss 
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Axio Imager inverted fluorescence microscope (Zeiss, Germany) and the AxioVision (V3.8.1) 
imaging software. 
 
2.4.1 pDNA Transfections  
 
Seeded cells were transfected with 250 ng/well each of pmRNA-CMV-MCS, pmRNA-
CMV-eGFP, pmRNA-CMV-LHBs or pmRNA-CMV-SHBs. An HBV replication-competent 
plasmid, pCH9-3091, was used as a positive control (Nassal, 1992). pmRNA-CMV-MCS was 
used as a mock control and pmRNA-CMV-eGFP was used for recording transfection efficiency. 
DNA transfections were performed using Lipofectamine
TM
 3000 reagent (Invitrogen, CA, USA) 
where the protocol was modified to accommodate a 48 well culture dish format. The transfection 
mix contained 250 ng of pDNA, 0.5 μl of P3000TM reagent and 0.4 μl of LipofectamineTM 3000 
in a total volume of 50 μl per well made up in Opti-MEMTM (Thermo-Scientific, MA, USA). 
The transfection reactions were mixed by vortexing for at least 3 seconds and then left to 
incubate for 20 minutes at RT before being added drop-wise to the cells. Otherwise, the protocol 
provided by the manufacturer was followed as instructed.  
Cells were left to incubate in the transfection mix for 8 hours at 37
o
C and 5% CO2 before 
the medium was replaced with fresh, pre-warmed Gibco
®
 DMEM (Life Technologies, CA, USA) 
supplemented with 10% heat-inactivated FCS, penicillin (10 000 units/ml) and streptomycin 
(100μg/ml). Transfected cells were incubated for a further 48 hours before being processed for 
intracellular and secreted HBsAg detection. 
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2.4.2 mRNA Transfections  
 
Seeded cells were transfected with 500 ng/well each of eGFP mRNA or TriLink eGFP 
mRNA to serve as transfection efficiency controls. TriLink Biotechnologies offers a service in 
the production of high-quality mRNA transcripts. Here we used their services to produce eGFP 
mRNA for use as a positive control. The eGFP mRNA produced from pmRNA-CMV-eGFP was 
also included in a transfection experiment prior to the initiation of in vitro mRNA transcript 
synthesis to establish the produced mRNA is translated using the lipofection method of 
transfection. An untransfected control was used as a negative control. Experimental cell samples 
were transfected with 500 ng/well of either LHBs mRNA or SHBs mRNA. As a positive control 
for immunofluorescence pCH9-3091 (Nassal, 1992) was used at a dilution of 150 ng/well. The 
mRNA transfections were performed using Lipofectamine
TM
 3000 (Invitrogen, CA, USA) 
applying a protocol similar to that used for pDNA transfections (section 2.4.1) in a 48 well 
culture dish with the exception that P3000
TM
 reagent was excluded from the transfection mix. 
The transfection reactions were mixed by vortexing for at least 3 seconds and then left to 
incubate for 20 minutes at RT before being added drop-wise to the cells. Otherwise the protocol 
provided by the manufacturer was followed as instructed. 
Cells were left to incubate in the transfection mix for 8 hours at 37
o
C and 5% CO2 before 
the medium was replaced with fresh pre-warmed Gibco
®
 DMEM (Life Technologies, CA, USA) 
supplemented with 10% heat-inactivated FCS, penicillin (10 000 units/ml) and streptomycin 
(100 μg/ml). Transfected cells were incubated for a further 48 hours before processing for 
detection of intracellular and secreted HBsAg. 
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2.5 Detection of HBsAg 
 
 Intracellular LHBs and SHBs was detected using immunofluorescence performed 
according to the protocol in appendix A2-3 and modified according to the optimised primary 
antibody incubation conditions (see section 2.2). Cells were fixed, permeabilized and prepared 
for immunofluorescence 48 hours post-transfection. 
Extracellular HBsAg was detected using an HBsAg-specific sandwich-type enzyme-
linked immunosorbent assay (ELISA). The supernatant of transfected cells was harvested 48 
hours post-transfection and processed using the Monolisa
TM
 HBsAg ULTRA kit (Bio-Rad, CA, 
USA) according to the instruction manual provided. Briefly, 100 μl of cell supernatant was 
added to respective wells on a 96-well microtiter plate coated with murine monoclonal 
antibodies specific for the S domain of HBsAg present in both LHBs and SHBs. A half-volume 
(50 μl) of Conjugate Solution was dispensed into each well and left to incubate, covered, in a 
37
o
C incubator. The conjugate solution contains monoclonal mouse and polyclonal goat anti-
HBsAg antibodies conjugated to peroxidase. The microtiter plates were then washed a minimum 
of 5 times using Washing Solution (provided by the kit) diluted to 1 × in dH2O. A 100 μl volume 
of development solution (provided by kit) was added to each well and the samples left to 
incubate a further 30 minutes at RT in the dark After the final incubation period, 100 μl of 
Stopping solution (1 N H2SO4; provided by kit) was added and left to incubate for 5 minutes at 
RT. The ELISA data were extracted as optical density measurements at 450/690 nm using the 
iMark Microplate Absorbance Reader (Bio-Rad, CA, USA). Captured data was processed using 
GraphPad PRISM
®
 software (V5.0). 
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3. RESULTS 
 
3.1 Generation of transcriptional templates and in vitro expression vectors  
 
 The pmRNA plasmid backbone designed for the purposes of mRNA synthesis 
(section 2.1.1) contains NcoI and PmeI restriction sites within the MCS. The NcoI site is located 
at the 3’ terminus of the 5’ UTR sequence and the PmeI site is located at the 5’ terminus of the 3’ 
UTR sequence. The restriction sites are absent from LHBs, SHBs and eGFP making them 
suitable choices for subcloning (Figure 9). The NcoI and PmeI restriction sites were introduced 
at the 5’ and 3’ termini of LHBs, SHBs and eGFP by modification of the forward and reverse 
primer sequences for PCR amplification (Table 2). Similarly, the CMV promoter/enhancer 
sequence was amplified from the pCI-neo-eGFP plasmid using PCR primers that introduced a 
BstXI site at the 5’ terminus and a SacI site at the 3’ terminus of the sequence (Table 2). High 
purity, homogenous solutions of the LHBs, SHBs, eGFP and CMV amplicons were obtained and 
the PCR conditions were considered optimal (Figure 11a). High fidelity amplification of the 
target sequences was confirmed by Sanger sequencing of the amplicons subcloned into 
pTZ57R/T backbone (see representative chromatogram in appendix A4-2). The pTZ clones 
containing sequences confirmed as being correct were prepared for downstream application. On 
average, out of 4-6 clones selected for sequencing, at least 2 harboured sequences matching the 
original sequence.  
Initially, LHBs, SHBs and eGFP sequences were excised from the positive pTZ clones 
and inserted into the pmRNA-MCS-95A backbone. Subcloning of the coding sequences was 
performed prior to subcloning of the CMV because of an NcoI site within the promoter sequence 
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(Figure 9). The final plasmid constructs are described in Table 1 and shown schematically in 
Figure 7. The CMV promoter/enhancer was included to drive protein expression from the pDNA 
in transfected Huh7 cells. T7 polymerase directs mRNA transcript synthesis from the T7 
promoter downstream of the CMV promoter/enhancer. Using this rationale, the ability for the 
LHBs, SHBs and eGFP to produce functional protein could be assessed before those same 
plasmids were used for in vitro transcription. Positive clones containing all the critical sequence 
elements indicated in Figure 7 were identified by restriction mapping. Restriction enzymes were 
chosen specifically to be diagnostic for the CMV promoter/enhancer and the protein-coding 
sequences (Table 5) in the correct orientations. Representative digestion reactions of positive 
clones are shown in Figure 11b.  
 SpeI cleaves the DNA within the CMV promoter/enhancer sequence and does not have 
any additional restriction sites within LHBs, SHBs or eGFP. SpeI is a unique cutter of the 
plasmid constructs and the presence of two bands within the SpeI and ScaI double digestion 
reaction indicates the presence of the CMV promoter/enhancer (Figure 11b). ApaLI digests the 
plasmid constructs at three different sites generating two bands of identical length for pmRNA-
CMV-LHBs and pmRNA-CMV-SHBs. The bands are 1250 bp and 500 bp in length (Figure 
11b). The third band is diagnostic of the presence of LHBs or SHBs. Therefore, pmRNA-CMV-
LHBs and pmRNA-CMV-SHBs contain the CMV promoter/enhancer and HBsAg-coding 
sequences as needed. EcoRI is a unique cutter and cleaves the DNA immediately downstream of 
the M13F. NotI is an enzyme of the MCS and therefore only cleaves pmRNA-CMV-MCS 
(Figure 11b). BamHI cuts within eGFP and the presence of a second band indicates the insertion 
of the eGFP sequence (Figure 11b). By this analysis, all the plasmid constructs were confirmed 
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as being correct and containing all the sequence elements needed for later use in mRNA 
production and in vitro expression experiments.  
 
Table 5: Predicted band sizes of positive clones following restriction digestion with multiple sets 
of restriction enzymes. 
Plasmid  Enzymes  Expected Band Sizes (bp) 
pmRNA-CMV-MCS 
SpeI and ScaI 
1000 
2800 
EcoRI and NotI 
800 
3000 
pmRNA-CMV-eGFP 
SpeI and ScaI 
1000 
3500 
EcoRI and BamHI 
2800 
1100 
700 
pmRNA-CMV-LHBs 
SpeI and ScaI 
950 
3900 
ApaLI 
3200 
1250 
500 
pmRNA-CMV-SHBs 
SpeI and ScaI 
950 
3400 
ApaLI 
2700 
1250 
500 
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Figure 11:Molecular cloning of mRNA production plasmids and in vitro expression vectors. a) 
Purified PCR amplicons. LHBs, SHBs, eGFP and CMV amplicons. b) Restriction mapping of 
constructed plasmids. Representative restriction digestion reactions of positive clones containing 
the CMV promoter/enhancer upstream of the T7 promoter and downstream coding sequences are 
shown. The O’GeneRulerTM DNA ladder mix (Thermo-Scientific, MA, USA) was run alongside 
the samples and undigested pDNA controls (Und) for size comparison. 
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3.2 Optimisation of immunodetection of intracellular HBsAg  
 
 Immunofluorescent detection of expressed HBsAg present in the cytosol of transfected 
cells was performed using three primary antibodies: (i) anti-S, (ii) anti-preS1 and (iii) anti-preS2. 
The use of three antibodies binding to three distinct regions of protein served a dual purpose. 
Firstly, binding of the antibodies would confirm the presence of intracellular HBsAg expressed 
from the codon-optimised constructs and secondly, preS-specific antibodies would distinguish 
between LHBs and SHBs. The antibodies were used at dilutions recommended by the 
manufacturer but the incubation conditions for each antibody needed to be optimised. Following 
the application of the standard immunofluorescent imaging protocol (Appendix A2-3) with one 
hour incubation in primary antibody at RT, no fluorescent signal was detectable above 
background.  
The imaged cells transfected with pmRNA-CMV-LHBs or pmRNA-CMV-SHBs were 
indistinguishable from the untransfected control and the control excluding primary antibody, 
indicating that non-specific binding of secondary antibody was not occurring. Instead, we 
reasoned that the primary antibodies were not binding sufficiently to the protein or that the 
protein was not being expressed at detectable levels from the pmRNA-CMV-LHBs or pmRNA-
CMV-SHBs. For optimisation independent of transfection we used HepG2.2.15 cells which 
constitutively express LHBs, MHBs and SHBs for optimisation of primary antibody incubation 
conditions. HepG2.2.15 cells are stably transfected with the complete genome of HBV and 
therefore constitutively express all three forms of HBsAg (Sells et. al., 1987). Thus, if we were 
able to detect HBsAg in HepG2.2.15 cells but failed to detect the same protein in transfected 
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cells using the same protocol, we could conclude that there was a problem with the coding 
sequences.  
Primary antibody-binding can be affected at two steps of the protocol, at the blocking 
step and at the incubation step. Three conditions were evaluated for each of the three antibodies, 
namely (i) incubation in primary antibody O/N at 4
o
C in a humidified chamber, (ii) incubation in 
blocking buffer, (1% w/v) BSA O/N at 4
o
C in a humidified chamber followed by an incubation 
in primary antibody for 1 hour at RT and (iii) incubation in primary antibody for 1 hour at RT. 
Anti-preS1 and anti-preS2 antibodies were used at a 1:100 dilution while anti-S was used at a 
1:50 dilution. Anti-preS1 and anti-S antibodies bind optimally following O/N incubation at 4
o
C 
in a humidified container. Anti-preS2 binds optimally when the cells are blocked in 1% BSA 
O/N at 4
o
C in a humidified container followed by one hour incubation in primary antibody at RT 
the following day (Figure 12). These conditions were applied in all later immunodetection 
protocols wherein the three antibodies were used. The lack of detectable signal above 
background in the control sample wherein incubation with primary antibody was omitted 
indicates there is no non-specific binding of secondary antibody within the samples and signal 
therefore originates from detected protein only.  
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Figure 12: Optimisation of immunofluorescence protocol using HepG2.2.15 cells. Three 
primary antibodies binding epitopes present within the PreS1, PreS2 and S regions were assessed 
for optimal binding and specificity using three different incubation or protocol conditions. (I) 
Incubation in primary antibody O/N at 4
o
C. (II) Incubation in blocking buffer (1% (w/v) BSA in 
PBS) O/N at 4
o
C before incubating in primary antibody for 60 minutes at RT. (III) Incubation in 
I II III 
No P Ab 
Anti-S 
Anti-PreS1 
Anti-PreS2 
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blocking buffer (1% (w/v) BSA in PBS) for 60 minutes at RT and then incubation in primary 
antibody for 60 minutes at RT. The anti-preS1 and anti-preS2 antibodies were used at a 1:100 
dilution; the anti-S antibody was used at a dilution of 1:50. A goat anti-mouse IgG secondary 
antibody conjugated to Alexa Fluor
®
 488 was used at a dilution of 1:200. A control sample in 
which a primary antibody incubation step was omitted (No P Ab) was included to demonstrate 
specificity of binding. Images were captured using the Zeiss Axio Imager inverted fluorescence 
microscope (Zeiss, Germany) and the AxioVision (V3.8.1) imaging software.  
 
3.3 CMV-driven production of native protein from subcloned genes 
 
Initially, Huh7 cells were transfected with pmRNA-CMV-eGFP (Figure 13). Fluorescent 
eGFP was detected indicating that the pmRNA-CMV plasmid construct design (Figure 7) was 
able to produce native protein despite the additional, unconventional sequence elements included 
in the mRNA transcripts upstream of the translational start site. The plasmids expressing eGFP 
also allowed for visual assessment of transfection efficiency using Lipofectamine
TM
 3000. To 
assess whether codon-optimised LHBs and SHBs inserted into the pmRNA-CMV backbones are 
expressed to produce LHBs and SHBs respectively, cultured Huh7 cells were transfected with 
pmRNA-CMV-LHBs and pmRNA-CMV-SHBs using the same transient transfection protocol 
used with pmRNA-CMV-eGFP. As a positive control for HBsAg expression, Huh7 cells were 
also transfected with pCH9-3091 (Nassal, 1992). Expression of LHBs, MHBs and SHBs from 
pCH9-3091 in cells of hepatic origin is driven by endogenous HBV promoters and therefore 
likely to occur at levels comparable to those noted during physiological HBV infection. 
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Transfection of Huh7 with pmRNA-CMV-MCS as a mock control validated that HBsAg 
expressed in Huh7 is only detected when HBsAg-coding DNA was present.  
Secreted HBsAg (LHBs and SHBs) was detected within the medium of Huh7 cells 48 
hours post-transfection by HBsAg-specific ELISA. The HBsAg ELISA detects only S protein 
region and therefore does not discriminate between LHBs and SHBs. SHBs expressed from 
pmRNA-CMV-SHBs is secreted at levels comparable to those of the positive control whereas 
LHBs was not detected in the media of cells transfected with pmRNA-CMV-LHBs (Figure 14). 
The data shown are mean OD490nm readings representative of experiments performed in triplicate 
with SEM shown (Figure 14). SHBs is thus readily secreted from transfected cells whereas 
LHBs is not. However, LHBs is expressed from pmRNA-CMV-LHBs but appears to be retained 
within the intracellular space (Figure 15).  
Huh7 cells transiently transfected with pmRNA-CMV-LHBs exhibited positive 
immunofluorescent signals when incubated with anti-preS1, anti-preS2 and anti-S antibodies 
(Figure 15). The same result was obtained for Huh7 transfected with pCH9-3091 (Nassal, 1992). 
In contrast, transfection with pmRNA-CMV-SHBs resulted in detectable signal only when 
incubated with anti-S antibodies (Figure 15) consistent with the absence of preS1 and preS2 
epitopes. We were able, therefore, to distinguish between LHBs and SHBs using the different 
primary antibodies. By qualitative assessment, LHBs appeared more abundant in the intracellular 
space than SHBs but anti-S antibodies detected far less of the S-domain in cells transfected with 
pmRNA-CMV-LHBs than pmRNA-CMV-SHBs (Figure 15). It cannot be excluded that anti-S 
binds its target with lower affinity than anti-preS1 or anti-preS2 which may account for the lower 
than expected levels of intracellular LHBs in the cells transfected with pmRNA-CMV-LHBs. In 
conclusion, native LHBs and SHBs is expressed from codon-optimised LHBs and SHBs 
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respectively and the pmRNA-CMV-LHBs and pmRNA-CMV-SHBs constructs were therefore 
used for in vitro transcription of synthetic LHBs and SHBs mRNA.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Efficiency of transient transfection protocol measured by eGFP expression. Huh7 
cells were transfected with pmRNA-CMV-eGFP and transfection efficiency was visually 
assessed by the apparent frequency of eGFP-positive cells within the overall population. Green 
fluorescence was detected using the Zeiss Axio Imager inverted fluorescence microscope (Zeiss, 
Germany) and the AxioVision (V3.8.1) imaging software. Shown here is a representative image 
of three separate experiments performed in triplicate. Cells are shown at 200× magnification. 
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Figure 14: Detection of HBsAg secreted from transfected Huh7.  Huh7 cells were transiently 
transfected with pmRNA-CMV-LHBs, pmRNA-CMV-SHBs, pmRNA-CMV-MCS (mock) and 
pCH9-3091 (positive control). The media removed from the cultures of transfected cells 48 hours 
post-transfection was subjected to an HBsAg ELISA for quantitative assessment of secreted 
HBsAg. Data are represented as mean optical density measurements (at 490nm) normalised to 
the mean measurement for the positive control (pCH9-3091) (+/- SEM, n=3). 
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Figure 15: Immunodetection of intracellular HBsAg. Immunodetection of intracellular LHBs 
and SHBs using anti-preS1, anti-preS2 and anti-S primary antibodies and an Alexa Fluor
®
-488 
conjugated secondary antibody. Green fluorescence was measured using the Zeiss Axio Imager 
inverted fluorescence microscope (Zeiss, Germany) and the AxioVision (V3.8.1) imaging 
software. Images shown are representative of experiments repeated in triplicate. Images are 
shown at 200× magnification and exposure for green fluorescence (FITC Filter) was kept 
constant at 500 ms. The cells were counterstained with DAPI. 
Anti-S Anti-PreS1 Anti-PreS2 
Mock 
pCH9-3091 
pmRNA-LHBs 
pmRNA-SHBs 
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3.4 mRNA Synthesis  
 
 Prior to inclusion in the T7 in vitro transcription reaction, the pDNA has to be linearised 
by restriction digestion. The linearisation step is critical to the success of the transcription 
reaction because incompletely linear DNA would result in a heterogeneous population of mRNA 
transcripts. The positioning of the linearisation restriction site dictates the universal termination 
point for all transcripts and ensures that they are all of similar length. The design of our pmRNA 
backbone includes a poly (A:T) sequence on the coding DNA strand. The stretch of 95 ‘T’ 
nucleotides is transcribed into a poly (A) tail mimic by in vitro transcription (Figure 10).  
Ideally, the final rNTP of the mRNA transcript should be rATP because the final dNTP 
on the linear pDNA is ‘T’. An attempt to achieve this was made by utilising SapI, a Type IIS 
restriction enzyme, for template linearisation. The SapI recognition site is just downstream of the 
poly (A:T) sequence while its restriction site is 5 nt into the poly (A:T) such that linearisation 
would result in ~90 thymidine nucleotides on the coding strand. However, there are two SapI 
recognition sites within the pmRNA constructs spaced approximately ~350 bp apart. Instead of 
cutting at both sites as expected, SapI usually cleaved the DNA only at one or the other 
restriction site (Appendix A4-1). The DNA template produced from SapI linearisation was a 
mixture of two different sizes which proved problematic for mRNA synthesis wherein use of the 
template mixture produced a heterogeneous mixture of transcripts of varying lengths (Appendix 
A4-1b). As an alternative to SapI, there is a HindIII restriction site ~8 nt downstream of the 
termination point of the poly (A:T). We opted to use HindIII instead because it is a robust, 
broadly used Type II restriction enzyme. Linearisation using HindIII was highly efficient and 
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only a negligible amount of DNA template is assumed to remain undigested, undetectable by 
standard agarose gel electrophoresis in a 1% agarose gel (Figure 16a).  
 When setting up in vitro transcription reactions and handling the mRNA product, great 
care needed to be taken to ensure that the mRNA did not become degraded. The mRNA was far 
less stable than DNA and is highly susceptible to digestion by ubiquitous RNases, a major 
contaminant of all laboratory surfaces and equipment. The mRNA production procedures were 
therefore carried out in strictly controlled environments using equipment and solutions reserved 
specifically for use with RNA. Formaldehyde-agarose gel electrophoresis was used not only to 
assess the homogeneity of the mRNA transcript population but also to ensure that the mRNA is 
intact. By our method, a pure, homogenous solution of mRNA was produced from each pmRNA 
template that was of high quality and contains no degradation products (Figure 16b). Within the 
linearised template there was only a single T7 promoter followed on by a single translational 
start site (Figure 7). It is reasonable to assume that only one type of mRNA transcript would be 
synthesised and that transcript would contain the sequence encoded for by the DNA template. 
Thus, no RNA ladder was included for size determination but differences in mRNA transcript 
length are evident in Figure 16b because of differences in the length of LHBs, SHBs and eGFP. 
Earlier, total RNA extracted from Huh7 showing the 18S and 23S was used to estimate mRNA 
transcript sizes (data not shown). The mRNA production protocol was successful and is 
considered optimal within the limitations of the kit used.  
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Figure 16: mRNA Synthesis. a) Linearisation of mRNA production plasmids. The mRNA 
production plasmids pmRNA-CMV-eGFP, pmRNA-CMV-LHBs and pmRNA-CMV-SHBs 
were linearised by digestion with HindIII. An undigested control was included (Und) to 
demonstrate linearisation. High purity linearised pDNA was included as the template for 
3000 
1000 
500 
pmRNA-CMV-eGFP pmRNA-CMV-LHBs pmRNA-CMV-SHBs 
a) 
b) 
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synthetic mRNA production by in vitro T7 transcription. b) In vitro transcribed mRNA. 
Synthetic mRNA produced from the linearised templates visualised by EtBr-staining in a 1% 
formaldehyde-agarose gel run at 80 V for 45 minutes. eGFP mRNA Produced by TriLink 
Biotechnologies, CA, USA (TriLink eGFP) was used as a quantity loading control and mRNA 
integrity control. 
 
3.5 Translation of the synthetic mRNA transcripts in transfected Huh7 cells 
 
The Huh7 cells were transfected with 0.5 μg of mRNA per well in a 48 well culture dish 
using Lipofectamine
TM
 3000. Lipofection is not an ideal method of transfection with mRNA 
transcripts; it is more common to use Nucleofection or electroporation to minimise the time of 
incubation before transfection and in doing so minimise the risk of degradation. Using eGFP 
mRNA produced by TriLink Biotechnologies or produced from pmRNA-CMV-eGFP, Huh7 
cells were transfected using the Lipofection method and eGFP expression was assessed using 
fluorescence microscopy (Figure 17). Increased frequency of GFP-positive cells following 
transfection with TriLink eGFP mRNA as opposed to eGFP mRNA produced from pmRNA-
CMV-eGFP could indicate a greater translational capacity of the TriLink mRNA (Figure 17). 
The TriLink mRNA contains similar sequence elements to the pmRNA templates: (i) the 5’ and 
3’ UTRs as well as the transcribed poly (A:T) sequence (albeit only ~50 ‘T’ nucleotides are 
present on the coding strand. However, the synthesis protocol is proprietary and it is not clear 
which method of production or purification is used. It is likely that a step included in the 
preparative protocols results in greater translational capacity over the mRNA produced by the 
method here described. Green fluorescent protein is produced from the eGFP produced by our 
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means indicating that synthetic transcripts are translatable albeit at lower levels than TriLink 
eGFP mRNA (Figure 17).  
 HBsAg-ELISA of Huh7 cell medium after transfection with LHBs and SHBs mRNA 
reveals a similar pattern of HBsAg secretion to that noted for Huh7 transfected with pmRNA-
CMV-LHBs and pmRNA-CMV-SHBs (Figure 18). Though not ideal, a lack of an mRNA-based 
positive control necessitated the use of pCH9-3091 to control for LHBs and SHBs detection 
intracellularly and within the cell media. SHBs secreted from cells transfected with SHBs mRNA 
is at levels comparable to the positive control whereas the secreted levels of protein resulting 
from transfection with LHBs mRNA are comparable to the untransfected, negative control 
(Figure 18). The most robust primary antibody as identified in previous experiments, namely 
anti-preS2, was used for immunodetection of intracellular LHBs. LHBs protein was detected 
within the intracellular space of Huh7 transfected with LHBs mRNA (Figure 19); however, the 
frequency of LHBs-positive cells was far lower than that noted after transfection with pmRNA-
CMV-LHBs. The LHBs translated from LHBs mRNA was also present at far lower levels within 
the transfected cells than that produced from pCH9-3091 (Nassal, 1992). These results show that 
both LHBs and SHBs proteins were translated from the synthetic mRNA transcripts. Therefore it 
was concluded that by our method, native protein is producible from synthesised mRNA in vitro. 
This is important for in situ antigen production whereby the native fold of a protein maintains 
structural epitopes important for the generation of functional antibodies. 
 
 
 
 
91 | P a g e  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Transfection of Huh7 cells with eGFP mRNA. Huh7 cells were transfected with 0.5 
μg TriLink eGFP and eGFP mRNA respectively. Transfection efficiency was visually assessed 
by determining the number of eGFP-positive cells within the overall transfected population. 
Green fluorescence was detected using the Zeiss Axio Imager inverted fluorescence microscope 
(Zeiss, Germany) and the AxioVision (V3.8.1) imaging software. Cells are shown at 100× 
magnification. 
 
 
 
 
 
 
 
Untransfected 0.5 μg TriLink eGFP 
mRNA 
0.5 μg eGFP mRNA 
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Figure 18: Detection of secreted SHBs from mRNA-transfected Huh7 cells. Huh7 cells were 
transiently transfected with LHBs mRNA, SHBs mRNA and pCH9-3091 pDNA (positive 
control). The media removed from the cultures of transfected cells 48 hours post-transfection 
were subjected to an HBsAg ELISA for quantitative assessment of secreted HBsAg (SHBs). 
Data are represented as mean optical density measurements normalised to the mean measurement 
for the positive control (pCH9-3091) (+/- SEM, n=9). Untransfected cells were used as a 
negative control. 
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Figure 19: Detection of intracellular LHBs translated from synthetic mRNA in Huh7. 
Immunodetection of intracellular LHBs using an anti-preS2 primary antibody and an Alexa 
Fluor
®
-488 conjugated secondary antibody. Green fluorescence was measured using the Zeiss 
Axio Imager inverted fluorescence microscope (Zeiss, Germany) and the AxioVision (V3.8.1) 
imaging software set on the FITC (Green) filter. Images are shown at 400× magnification and 
exposure for green fluorescence (FITC filter) was kept constant at 1.5 s. Cells are counterstained 
with DAPI. LHBs is detected in the cytosol of cells transfected with pCH9-3091 (positive 
control) and LHBs synthetic mRNA. 
Anti-PreS2 
Untransfected 
pCH9-3091 
LHBs mRNA 
94 | P a g e  
 
4. DISSCUSSION 
 
4.1 Synthesis of LHBs and SHBs mRNA 
 
 Vaccine formulations containing antigen-encoding mRNA have proven antiviral potential 
and increased research efforts will further strengthen development of this field.  Our study relates 
to the adaptation of antiviral mRNA vaccination strategies for dual application in anti-HBV 
prophylaxis and therapy for CHB. This study describes the developmental stages of an anti-HBV 
mRNA-based vaccine wherein we successfully produced high quality LHBs- and SHBs-
encoding synthetic mRNA transcripts that were translated in cultured cells to produce detectable 
LHBs and SHBs protein. 
The method of mRNA production by in vitro transcription is the most common approach 
to mRNA synthesis. However, any fault in the design of the template pDNA or in the production 
process itself can result in the inability to produce mRNA of sufficient quantity and quality, as 
well as mRNA having compromised translational capacity. There are several factors critical to 
the rational design of an mRNA production template and process which include: (i) 
translatability of the encoded mRNA, (ii) choice of linearisation enzyme, (iii) inclusion of 
application-appropriate regulatory sequences (5’ and 3’ UTRs) and (iv) structural resemblance of 
the mRNA transcripts to endogenous mRNA.  
Codon-optimisation of the protein-coding sequence was a crucial aspect of the rational 
design process. The genetic code is degenerate and thus as many as six different codons can 
encode a single amino acid. The tRNA-gene copy numbers within the genomes of various 
multicellular eukaryotic organisms including Homo sapiens and Drosophila melanogaster 
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revealed that differential codon usage in eukaryotes is significant (Kanaya et. al., 2001). Biased 
codon usage can diminish interspecies translational efficiency of exogenous DNA or synthetic 
transcripts with consequences for antigen production from nucleic acids in vaccine formulations. 
The immunogenicity of a polynucleotide vaccine encoding the L1 and L2 capsid proteins of 
human papillomavirus was significantly improved after codon optimisation of the protein-coding 
sequences (Liu et. al., 2001). Heterologous L1 and L2 proteins produced from the modified 
DNA sequence induced neutralising, protective antibody responses and potent CTL responses in 
immunized mice. Codon-optimisation is readily applied in the production of sequence-
engineered templates for synthesis of mRNA transcripts used as high-expression genetic vectors 
for antigen expression (Thess et. al., 2015). Here, the coding sequence for LHBs and SHBs were 
codon-optimised for expression in humans (primary organism) and in mice (secondary 
organism). 
Codon-optimisation for optimal production of heterologous protein relies on a central 
assumption that the incorporation of frequently used codons to replace rarer codons in a given 
sequence results in high level protein expression. A seminal study carried out in 2009 (Kudla et. 
al., 2009) showed that applying randomly selected codon usage to generate a library of 154 GFP 
genetic variants resulted in as much 250-fold variation in functional GFP production when 
comparing the low-expression and high-expression library constructs. Interestingly, low level 
production of GFP did not correlate with rare codon usage but rather cell fitness. It appears that 
mRNA transcripts containing high frequencies of rare codons compromised cell viability 
resulting in lower fluorescence (GFP expression). Within the context of generating mRNA for 
optimal antigen production, one cannot rely on codon-optimisation alone. Specific regulatory 
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sequences as well as inclusion of the Kozak sequence (Kozak, 1978) may act synergistically to 
promote mRNA stability and optimal translational capacity (Pascolo, 2008).  
The translational start codon is included within the Kozak sequence and the translational 
stop codon concludes the codon-optimised protein-coding sequence at the 3’ terminus. Between 
the T7 promoter and the translation initiation signal, as well as between the translation 
termination signal and the start of the poly (A), are stabilization and destabilization sequences 
that contribute to the highly regulated half-life of mRNA transcripts (Ross, 1995). The mRNA is 
stabilised by pyrimidine-rich sequences in the 3’ UTR which are responsible for binding to the 
‘α-complex’ (Holcik & Liebhaber, 1997). Therapeutic mRNA molecules and those used for 
prophylaxis commonly include the 5’ and 3’ UTRs of the β- and α-globin genes respectively 
because they have been found to promote long-term stability of mRNA in anucleate red blood 
cells (Malone et. al., 1989). The UTR sequences act to promote stability concurrently with the 
length of the poly (A). An optimal length of the poly (A) has been determined as being more 
than 100 nt but no less than 30 nt (Mockey et. al., 2006; Holtkamp et. al., 2006). In the design of 
our pDNA templates, the 5’ UTR of β-globin and 3’ UTR of α-globin were included and a poly 
(A) tail of approximately 95 nt was transcriptionally introduced to maximise stability of the 
synthesised mRNA.  
The length of the poly (A) tail may have a significant impact on the success of an mRNA 
vaccination construct. Typical eukaryotic mRNAs have a poly (A) tail between 80 and 200 nt 
long (Dreyfus & Regnier, 2002), while prokaryotes produce RNA with a poly (A) of between 30 
and 60 nt if at all (Sarkar, 1997). The innate immune system uses poly (A) tail length as a 
distinguishing molecular factor between endogenous and pathogen-associated mRNAs. mRNA 
lacking a long poly (A) upregulates IL12 secretion by transfected APCs (Koski et. al., 2004). 
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IL12 acts to polarise T-cells towards a TH2 response and in doing so promote B-cell expansion, 
increased secretion of IgM as well as activation of macrophages. The TH2 response is skewed 
towards supporting humoral immunity and limiting the spread of extracellular pathogens; 
induction of high-level IL12 could elicit protective antibody responses in vaccine recipients. 
Maximisation of IL12 secretion by maturing DCs requires two signals, a priming signal from 
IFN-γ and a secondary signal from binding to CD40L. Immunogenic mRNA can substitute the 
priming signal and thus, poly (A) length is an important consideration for mRNA vaccine design 
(Koski et. al., 2004). Vaccine efficacy would depend on balancing translational efficiency with 
intrinsic adjuvanticity. In the context of the study here described, the impact of the poly (A) tail 
length on translatability, and the relevance thereof in the context of vaccine design will be 
discussed in greater detail in section 4.2. 
The synthetic mRNA constructs have been designed to closely mimic endogenous 
mRNA molecules by transcriptional inclusion of the poly (A) and a 5’ cap dinucleotide 
analogue.  Inclusion of the standard Cap analogue in the in vitro transcription reaction typically 
results in around 80% capping efficiency. Standard Cap can be incorporated into the transcript in 
one of two orientations. Only the orientation whereby the 3’ OH of the pentose, which harbours 
the unmethylated guanine, is used for phosphodiester linkage to the nascent mRNA produces 
translatable mRNA. Thus, only 40% of transcripts produced would be translated into protein 
(Stepinski et. al., 2001). The use of an anti-reverse cap analogue (ARCA) overcomes this 
problem and allows for generation of 80% translatable transcripts with a five-fold increase in 
protein yield over standard-capped mRNA (Stepinski et. al., 2001). The ARCA here used is 
included in the mMessage mMachine
®
 T7 ULTRA kit (Thermo-Scientific, MA, USA) and is the 
subject of proprietary information. Alternatives to ARCA are currently under investigation in an 
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attempt to avoid the use of previously patented material in the production process and therefore 
reduce cost without compromising translation.  
The choice of restriction enzyme used for template linearisation is a critical stage of the 
design process. As a result of the RNA-dependent-RNA polymerase activity and processivity of 
the T7 bacteriophage polymerase (Arnoud-Barbe, 1998), an enzyme that does not produce 3’ 
overhangs must be used to avoid the production of larger-than-desired transcripts. The 
linearisation enzyme must digest the entire template DNA content of the reaction with high 
fidelity to avoid transcription of non-target sequences (Schlake, et. al., 2012). Initially we 
utilized SapI, a Type IIS restriction enzyme, for template linearisation (Appendix A4-1). SapI 
appeared to cleave the DNA only once in some instances, at one or the other SapI site. As a 
result, a doublet of linearised template was produced wherein the linear DNA fragments differed 
by approximately 350 bp (Appendix A4-1). 
To improve the efficiency of the linearisation reaction we chose to use HindIII as an 
alternative to SapI. HindIII  cuts DNA with the characteristics necessary to conform to the 
requirements of the mRNA production protocol and a cleavage efficiency of as much as 100% 
was achieved by HindIII digestion (Figure 16 a). However, the location of the HindIII site within 
the template DNA is not ideal and linearisation results in an 8 nt extension on the 3’ end of the 
poly (A) tail mimic with as yet unknown consequences on translational efficiency. Future effort 
would need to modify the template to exclude or minimise the nonessential additional 
nucleotides. Our method of mRNA production yielded a homogeneous preparation, free of 
transcripts of irregular length and of sufficient quantity for downstream experimentation (Figure 
16 b). The production procedure was highly reproducible and considered optimal for fulfilling 
the purposes of the current study. 
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4.2 Translation of synthetic mRNA to produce LHBs and SHBs 
 
Inclusion of a CMV promoter/enhancer upstream of the mRNA production sequences 
(Figure 7) allowed for assessment of surface antigen expression from the codon-optimised 
sequence prior to the initiation of mRNA production. Detectable surface antigen was produced 
from the pDNA harbouring LHBs and SHBs in cultured Huh7 (Figure 14; Figure 15). 
Quantification of extracellular or secreted surface antigen by ELISA revealed that the amount of 
SHBs produced from pmRNA-CMV-SHBs was comparable to that of the positive control 
(pCH9-3091) (Figure 14). LHBs, however, was detectable only within the intracellular space 
(Figure 15) and does not appear to be secreted from the cells (Figure 14). The observation that 
LHBs is not secreted when expressed as a heterologous protein concurs with observations made 
in previous studies (Chisari et. al., 1986; Cheng et. al., 1986).  
Translation of SHBs and LHBs from the synthetic mRNA transcripts was achieved 
within the cultured cells indicating that the rational design process had been successful. SHBs 
expressed from SHBs mRNA and subsequently secreted was detected at levels comparable to the 
positive control by ELISA while LHBs protein was not (Figure 18) confirming that inhibition of 
secretion occurs post-translationally. LHBs expressed from synthetic mRNA was detected within 
the cell (Figure 19) albeit at far lower levels than those seen post-transfection with the pDNA 
equivalent of the LHBs sequence (Figure 15). Furthermore, the eGFP mRNA transcript 
synthesised by our method as opposed to that synthesised by TriLink Biotechnologies produced 
eGFP at notably lower levels (Figure 17). We identified four possible explanations for this: (i) 
the transfection method may be suboptimal (ii) the stability of the mRNA may be compromised, 
(iii) the additional 8 nt at the 3’ terminus that remain as a product of the location of the HindIII 
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site during linearisation may negatively impact translational capacity or (iv) the length of the 
poly (A) may be insufficient.  
The preferred method of evaluating protein expression from mRNA in vitro is by 
nucleofection or electroporation. Lipofection in this instance did result in detectable protein 
levels (Figure 17) and the cells expressing eGFP from TriLink eGFP mRNA or our transcripts 
were transfected using a similar protocol. Lipofection, therefore, cannot account for differences 
in translational capacity but it may be worthwhile to utilise Nucleofection or electroporation in 
later experiments to optimise detectable protein output. It is possible that the TriLink mRNA is 
more stable; however, the UTR sequences for both TriLink transcripts and our transcripts are 
derived from globin genes.  Chromatographic recovery of mRNA as is applied at TriLink may 
remove destabilising contaminants carried over from the transcription reaction but more 
thorough investigation is needed to substantiate this. It is most likely that the additional 8 nt 
proceeding from the 3’ terminus of the mRNA or the length of the poly (A) affects translational 
capacity. 
The 5’ Cap and the poly (A) tail have mutually dependent functions in regulating the 
translation of endogenous and synthetic mRNA (Gallie, 1991). Poly (A) binding protein (PAB), 
a highly conserved eukaryotic protein (Grange et. al., 1987), functions as a regulatory 
determinant of translation by affecting the functioning and biogenesis of the 60S ribosomal 
subunit as well as the formation of the ribosomal complex between 60S and 80S ribosomal 
subunits (Sachs et. al., 1987). The poly (A) tail acts in trans with the 5’ Cap to bind translational 
initiation factors and regulate protein production (Gallie, 1991). A poly (A) tail of 95 nt may be 
insufficient in directing the appropriate molecular binding events for optimal translation 
efficiency. It may be possible to overcome this by excluding the poly (A:T) sequence from the 
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pDNA template and instead including the mRNA in a post-transcriptional poly (A)-tailing 
reaction. By this method, however, the length of the poly (A) is not easily controlled and may 
exhibit a high degree of variability within a given preparation of mRNA transcript. An unknown 
poly (A) length is undesirable for GMP-mRNA production and a longer poly (A) may have 
unforeseen effects on vaccine efficacy. It is recommendable to eliminate all other options to 
improve translational capacity before altering the method of poly (A) tail addition. 
 
4.3 Secretory capacity of expressed LHBs and SHBs 
 
LHBs is a large ORF containing three translation start sites and terminated by a shared 
stop codon (Figure 1). Therefore, all three forms of HBsAg share a common C-terminal S 
sequence (major surface protein) while the MHBs contains an additional preS2 region and the 
LHBs contains both a preS1 (at the N-terminus) and preS2 region.  The ELISA antibodies are 
directed against the S portion (major surface antigen) of the protein present in both LHBs and 
SHBs. Therefore, this assay should detect any HBsAg present extracellularly regardless of which 
form of the protein is present. The lack of detectable secreted LHBs (Figure 14 and Figure 18) is 
probably not as a result of assay limitations; however, an ELISA microtiter plate coated with 
anti-preS1 or anti-preS2 antibodies could be used to unequivocally prove this assumption. Bound 
antigens would be detected using a secondary antibody-conjugate detection system. 
The LHBs gene in the pDNA and LHBs mRNA contain all three transcriptional and 
translation start sites needed to produce LHBs, MHBs and SHBs. During a natural replication 
cycle of HBV, the three forms of the surface antigen are produced at varying levels and actively 
secreted (Ganem, 1996). There are two surface promoter elements and the stronger element 
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directs translation of SHBs (Ganem, 1996). It would be expected then that SHBs would also be 
produced from the LHBs pDNA and mRNA but this is not confirmed by the ELISA data (Figure 
14; Figure 18). The relative distribution of LHBs, MHBs and SHBs remains similar within the 
Dane particles, 22 nm subviral spheres and filaments (Gerin et. al., 1983; Theilmann et. al., 
1986). LHBs is co-secreted with the Dane particle and enriched within the 22 nm subviral 
filaments relative to SHBs and MHBs, which are more abundant in the 22 nm spheres relative to 
LHBs (Gerin et. al., 1983; Takahashi et. al., 1986). The 22 nm subviral spheres constitute the 
dominant form of secreted HBsAg and the relatively low levels of LHBs within these particles 
may serve to explain low level secretion of LHBs present in patient serum (Theilmann et. al., 
1986). 
In transgenic mice, increased production of LHBs resulted in a significant decrease in 
SHBs detected in the serum (Chisari et. al., 1986). Normally, SHBs is readily secreted and 
present at very low levels within the cytosol. Based on a property of the preS protein regions, 
and in particular preS1, LHBs in excess supresses the secretion of SHBs and causes it to be 
retained within the Golgi apparatus (Chisari et. al., 1986). It is likely, therefore, that the 
heterologous expression of LHBs ultimately inhibits the secretion of the other forms of HBsAg. 
However, secretion of SHBs produced from pCH9-3091 (Nassal, 1992) is unaffected by the 
LHBs produced from the same vector (Figure 14). Possibly, the endogenous HBV sequences 
within pCH9-3091 (Nassal, 1992) limit the production of LHBs, which subsequently permits 
continual secretion of SHBs as per the normal replication cycle. In terms of in situ antigen 
expression for immunisation purposes, LHBs would need to be secreted in order to taken up by 
APCs and processed for MHCII-restriction and induction of humoral responses. 
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Self-assembling protein nanoparticles in the form of virus-like vesicles (VLVs) have 
been assessed for anti-HBV therapeutic vaccination potential (Reynolds et. al., 2015). 
Administration of a VLV-vector additionally encoding MHBs in mice resulted in CTL responses 
detectable by ELISPOT assay. MHBs-specific antibody responses were shown but no direct 
assay on secreted MHBs was performed. It would be interesting to assess whether MHBs alone 
is more readily secreted than LHBs. The contribution of preS1 and preS2 to intracellular 
retention of surface antigen remains unclear (Chisari et. al., 1986). During nucleocapsid 
assembly and maturation, the preS1 domain is embedded in the envelope of the virion and faces 
the interior of the viral particle (Figure 2 b). The N-terminus becomes myristoylated (Persing et. 
al., 1987) and LHBs undergoes complex post-translational translocation (Lambert et. al., 2001) 
allowing for the PreS1 region to be exposed on the virion surface capable of mediating 
interactions with NTCP (Yan et. al., 2012). It is possible that a putative feature of the PreS1 
region, known to embed the protein in the membrane, does not undergo post-translational 
modification in the absence of other HBV proteins and as a result accumulates in the Golgi. 
Exclusion of the PreS1 region may restore secretory capacity but at the expense of including 
critical epitopes directing potentially-broadly neutralizing antibody responses. 
LHBs cannot be produced recombinantly in yeast (Imamura et. al., 1987) and attempts 
made to produce the protein using mammalian cells (Chisari et. al., 1986) proved that the 
application of the protocol would be insufficient for large-scale immunogen production. As the 
protein is not secreted at high levels (Chisari et. al., 1986), recovery and purification of 
recombinant membrane-bound LHBs from within intracellular organelles would be costly and 
laborious. Furthermore, induction of robust cell-mediated and humoral immune responses after 
administration of a nucleic acid-based vaccine depends on high-level secretion of the encoded 
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immunogen. Possible future work could investigate directing LHBs to the secretory pathway 
through inclusion of a signal sequence produced in the encoded antigen at the N-terminus. 
Simultaneous targeting of APCs in preference to non-immune cells could further promote the 
elicitation of protective and therapeutic immune responses (Boyle et. al., 1997; Hung et. al., 
2001). 
 
4.4 Synthesised mRNA within the context of a vaccine formulation 
 
 In recent years, the application of mRNA-based vaccination has gained increasing 
attention in various fields of medical research including anti-tumour vaccination (Boczkowski et. 
al., 2000), anti-allergy (Weiss et. al., 2010) and antiviral therapeutic vaccination (Martinon et. 
al., 1993). The mRNA biomolecule is biologically labile, highly programmable and intrinsically 
immunogenic making it an ideal alternative to DNA for development of novel vaccination 
strategies. mRNA offers some distinct advantages when compared with DNA: (i) when injected 
into murine skin, protein produced from naked mRNA exceeds the amount produced from naked 
pDNA of similar molarity (Probst et. al., 2007), (ii) mRNA is a transient biological 
macromolecule and the protein product is produced over a limited, controllable time period and 
(iii) exogenous mRNA can in no way alter the genetic material of a recipient cell and there is 
little to no risk of associated genotoxicity (reviewed in: Pascolo, 2008).  
Vaccination of patients with a repertoire of autologous tumour antigens in the form of 
total tumour mRNA is a viable option to overcome immune tolerance and promote tumour 
destruction (Boczkowski et. al., 2000). Anti-tumour mRNA vaccines encompassing mRNA 
amplified from tumour tissue promote survival in tumour-bearing mice (Ashley et. al., 1997) and 
105 | P a g e  
 
supress the formation of metastases (Boczkowski et. al., 1996). Developmental research into 
mRNA vaccine formulations produced by virtue of rational design and in vitro transcription is 
still in its infancy. An mRNA vaccine against influenza virus developed in 1993 (Martinon et. 
al., 1993) is the first example of a prophylactic and therapeutic mRNA vaccine with proven 
antiviral effect. Immunization of mice with liposomes loaded with mRNA encoding the 
influenza nucleoprotein induced potent antigen-specific CTL responses. The genomes of the 
mice carried one of three distinct MHC haplotypes and the induction of CTL responses was 
similar in all experimental groupings. The results suggest that antigens expressed from minimal 
genetic vectors such as mRNA circumvent MHC haplotype restrictions allowing for induction of 
protective antiviral immunity regardless of MHC genetic limitations on peptide presentation.  
Influenza viral infections represent a unique health challenge on a global scale because 
pandemic strains can arise rapidly and unexpectedly. As mRNA is highly programmable, the 
encoded sequences can be quickly altered to sequence-match changes in immunogenic proteins 
and produced for large-scale administration without reinitiating clinical testing (Petsch et. al., 
2012). In similar circumstances, towards the end of 2016 there was an unexpected outbreak of 
Zika virus (ZIKV) in South America with devastating neuropathological consequences for 
infected adults and infants (Pierson & Graham, 2016). Vaccination with nucleoside-modified 
mRNA encoding the pre-membrane and envelope glycoproteins of ZIKV has been recently 
proposed as a highly effective, potent immunization strategy for the prevention of future 
outbreaks (Pardi et. al., 2017).  
The ZIKV mRNA vaccine formulation was designed in accordance with many of the 
principles here discussed. The mRNA was produced by in vitro transcription and a 101 nt poly 
(A) tail mimic was encoded for by the pDNA template (Pardi et. al., 2017). The envelope 
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protein-coding sequences were also codon-optimised. However, the production process differed 
from that described here in that the synthesised mRNA transcripts were post-transcriptionally 
capped with ARCA in a separate reaction and the mRNA was recovered and purified by 
chromatography. Whereas we chose to rely on sequence-engineering of the template pDNA 
alone to optimise mRNA production and translation, Pardi and colleagues opted for the use of 
chemically-modified nucleotides, namely 1-methylpseudouridine-5’-triphosphate. The approach 
of using chemically-modified bases in an mRNA vaccine was successful in eliciting robust, 
protective antibody production in animal models and thus this method of mRNA optimisation 
does not appear to interfere with induction of humoral immunity. However, the vaccine 
formulation was tested prophylactically and not therapeutically. It is not conclusive from the data 
as to whether base modification will undermine induction of cellular immune, cytotoxic 
responses as is needed for the treatment of CHB. It is worth exploring if the inclusion of 
modified bases will rectify the low level expression noted in vitro (Figure 19) without 
compromising therapeutic vaccine efficacy at a later stage of development. 
Recombinant HBsAg anti-HBV vaccines, in contrast to nucleic acid vaccine, do not have 
potential use for therapy. Vaccines based on recombinant proteins are unable to elicit potent cell-
mediated immune responses in human recipients (Shen et. al., 2010; Chen et. al., 2011) which 
are essential for promoting viral clearance. DNA-based antiviral vaccine platforms have proven 
ability to activate humoral and cell-mediated antigen-specific immunity in small-animal models, 
primates and humans (Mallilankaraman et. al., 2011; Belisle et. al., 2011; Bagarazzi et. al., 
2012). Upon administration, the majority of the nucleic acid (DNA or mRNA) will most likely 
be taken up by and translated within non-immune cells. Intracellular proteins degraded within the 
proteasome are presented to surveiling immune cell by MHC-I restriction (Figure 5) and 
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abnormal, or viral-derived peptides and immune cells would stimulate TH1-polarised responses. 
In contrast, the antigens produced would ostensibly need to be secreted and then taken up by 
APCs to be processed for MHC-II restriction to elicit a TH2 antibody response (Figure 5). A 
means of overcoming the limitation of antigen-secretion would be to reprogram DCs ex vivo for 
antigen-production (Boczkowski et. al., 2000) or attempt to target pDCs directly in vivo by using 
appropriate methods of delivering the mRNA (Wang et. al., 2016). The efficiency and ultimate 
effectiveness of a prophylactic and therapeutic anti-HBV nucleic acid vaccine, therefore, would 
depend on the secretion of the encoded HBV immunogen, in this instance LHBs. This would 
need to be carefully addressed in the further development of the mRNA-vaccine formulation 
here described.  LHBs secretion would need to be promoted or an APC-targeted delivery method 
implemented using chemically modified lipid nanoparticles (LNPs). 
An anti-HBV DNA vaccine formulation designed by Obeng-Adjei and colleagues in 
2013 comprised consensus core and surface antigen sequences, including LHBs, from HBV 
genotypes A and C administered concurrently as a multivalent vaccine cocktail (Obeng-Adjei et. 
al., 2013). The DNA vaccine cocktail was able to activate polyfunctional T-cell responses in 
immunized mice and rhesus macaques with the effect of inducing potent HBV-specific CTL 
activity and generation of high-titer, cross-reactive protective antibodies (Obeng-Adjei et. al., 
2013). No experiments directly measuring secreted LHBs were reported in the 2013 study; 
however, the data indicate preS1- and preS2-specific CTL responses which corroborate with 
successful MHC-I and MHC-II peptide restriction.  
It is possible that the co-administration of consensus core sequences with surface antigen 
promoted the secretion of viral-like particles (VLPs) in which LHBs was incorporated. 
Interactions between the LHBS within the envelope and the underlying core proteins of the 
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nucleocapsid function in viral assembly and maturation before non-cytolytic release of the 
virions into the extracellular space (Hollinger, 1996). Artificially replicating these interactions 
may permit LHBs secretion as part of a VLP. Such an approach could be applied to improving 
the secretion profile described here. As a future objective of the current study, co-transfection 
with pDNA encoding core sequences and pmRNA-CMV-LHBs could be applied to assess the 
impact of the core protein on promoting LHBs secretion. If such an approach were to be 
successful, it may be necessary to deliver the mRNA vaccine as a mixture of LHBs and core 
mRNA for enhanced efficiency.  
Highly conserved N-terminal sequences of LHBs including the N-terminal aa 9-
NPLGF(F/L)P-15 of the preS1 (Figure 2 b) are crucial for mediating viral entry (Barrera et. al., 
2005). Making these sites unavailable for receptor-binding essentially blocks the infection or re-
infection cycle. A peptide, Myrcludex B, inhibits HBV entry by blocking the N-terminal aa 9-
NPLGF(F/L)P-15 and is currently in phase 2 of clinical trials (reviewed in: Urban et. al., 2014). 
Ostensibly, anti-preS1 antibodies would occlude receptor-binding and prevent receptor-mediated 
endocytosis. Inclusion of the preS1 protein domain in a vaccine formulation would prevent de 
novo infection and if administered to CHB patients undergoing liver transplantation surgery, 
could prevent reinfection of the newly transplanted liver. Also, inclusion of preS1 and preS2 
protein domains in a vaccine formulation may establish rapid seroprotection in previous non-
responder vaccine recipients (Rendi-Wagner et. al., 2006). It is critical, therefore, that future 
efforts be made to ensure that LHBs becomes the primary, functional immunogen of the mRNA 
vaccine here described to fulfil the therapeutic and prophylactic potential.  Furthermore, 
inclusion of a TLR9 agonist as a vaccine adjuvant may support immunogenicity of the vaccine 
formulation by activating the necessary effector cell populations (Steinhagen et. al., 2011).  
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The production of mRNA for clinical application is scalable and can be made to adhere to 
good manufacturing practice (GMP) regulations. Our method of production represents a pre-
GMP phase of development and would need to be modified at a later stage in consideration of 
GMP requirements. For example, the preparation of the pDNA template required culturing of 
bacterial clones in an ampicillin-containing bouillon (LB) (Appendix A2-1). GMP insists that 
because of the prevalence of penicillin allergies and the spread of penicillin-resistance, no 
antibiotic utilised at any stage of the mRNA preparative process should be of the ampicillin 
family (Pascolo, 2008). The mRNA produced was recovered from the T7 transcription mix by 
precipitation in lithium chloride precipitation solution (section 2.3). GMP mRNA must be 
recovered by size exclusion chromatography (SEC) within a buffer system containing only 
sodium ions. SEC allows for the elimination of aberrant or irregular transcripts as well as trace 
contaminants introduced during the enzymatic transcription process. Future development of the 
methodology here described will aim at complying with GMP standards. 
 
5. CONCLUDING REMARKS  
 
 The aim of the study here described was to design and implement an mRNA production 
procedure for the ultimate purpose of being included in an anti-HBV prophylactic and 
therapeutic vaccine formulation. To the best of our knowledge such an approach has not yet been 
applied to HBV therapy and the proven efficacy of such a vaccine would have significant impact 
on the field of HBV immunotherapy development. As noted earlier this year (2017) with the 
successful development of an anti-ZIKV mRNA vaccine (Pardi et. al., 2017), mRNA vaccination 
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is a valid and potentially valuable novel approach to antiviral prophylaxis. We hope to 
demonstrate its application as an effective immunotherapy in the near future. 
 The most critical aspect of the early stages of mRNA vaccine development is the 
successful generation of high quality, high purity mRNA transcripts that are translated to give 
functional protein or antigen. We were able to produce high quality mRNA transcripts that were 
translated into detectable LHBs and SHBs in vitro in transfected Huh7 using a highly 
reproducible method. However, the LHBs protein was translated at lower than anticipated levels 
in vitro and was not readily secreted as is a requirement for a successful mRNA-base therapeutic 
vaccine. LHBs is accepted as being a difficult protein to produce by heterologous expression and 
is retained within membranous organelles in the cytosol rather than entering the secretory 
pathway. The efficacy of the anti-HBV mRNA vaccine, particularly in the context of a 
prophylactic vaccine, may depend on the secretion of LHBs. Future efforts will  be directed at (i) 
improving the secretory profile of the LHBs protein, (ii) scaling up the production procedure 
within the parameters of GMP, (iii) assessment of base modification as a means to optimise 
antigen expression in vivo, (iv) design of a LNP-based delivery method for direct targeting of 
APC and (v) testing vaccine efficacy in vivo.  
The results of this study are promising and it is likely that the antigens produced from the 
mRNA in vivo would elicit immune responses in the recipient animal. This study will be 
expanded to include development of a nanoparticle-based delivery platform inclusive of an 
appropriate TLR9 adjuvant. Thus, future work will provide an intersection of multiple disciplines 
within anti-HBV research and its success will contribute to the advancement of anti-HBV 
prophylaxis as well as the therapeutic outcome of CHB treatment.  
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APPENDIX 
A1 ADDITIONAL SEQUENCE INFORMATION AND PLASMID MAPS 
A1-1 pmRNA-MCS-95A Sequence Insert  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A1-2 Available restriction sites in MCS 
 
 
 
 
A2  
 
 
 
 
 
>pmRNA-MCS-95A Insert: Coding strand (3’-5’) 
 
CACGTGGTATACCATTTTGCTGCCGGTCACTTAAAGCTCGAGCCATGGATTATGCTGAGTGATATCCCT
TTATTCTCTCTTTTCTTCTCATTCTTCTTTATATCGGCGGTGGTACCGCGCGGACGTCCGCCGGCGATC
GGGCCCTCTAGAATTAATTCCCGGGCAAATTTGCGACGGAAGACGCCCGAACGGAAGACCGGTACGG
GAAGAAGAGAGGGAACCGTGGACATGGAGAACCAGAAACTTATTTCGGACTCATCCTTCCGATCTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCTTCTCGTTCGAACCGCATTAGTACCAGTATC
GACAAAGGACTGTACACTCGTT 
 
Sequence Information: 
 T7 promoter sequence shown in green 
 5’ and 3’ UTRs are underlined  
 Kozak sequence is shown in purple  
 MCS is shown in red 
 Poly A:T sequence is shown in blue  
112 | P a g e  
 
 
 
GENERAL LABORATORY METHODS AND PROTOCOLS  
A2-1 Production and Purification of Plasmid DNA 
Reagents 
Luria Bertani Medium & Agar Plates  
Luria Bertani Medium (LB) was prepared by dissolving 10% (w/v) of tryptone (Sigma-Aldrich, 
MO, USA), 5% (w/v) of NaCl and 5% (w/v) of yeast extract (Sigma-Aldrich, Y1625) in 
deionized water (dH2O). LB medium for agar plates was prepared in the same way but 1.5% 
(w/v) of bacteriological agar (Sigma-Aldrich, MO, USA) was included in the recipe. The 
solution was sterilized by autoclaving at 121
o
C for 20 minutes and left to cool at room 
temperature (RT); the LB medium was stored at RT. For pouring plates, agar-containing LB 
solution was allowed to cool to ~60
o
C and was then treated with 1000X ampicillin (to a final 
concentration of 1X), mixed thoroughly and then poured into plastic bacterial petri dishes. The 
agar plates were left to polymerise at RT and then stored at 4
o
C for no longer than 1 month. 
1000X Ampicillin 
One gram of ampicillin (Sigma-Aldrich, MO, USA) was dissolved in 10ml of 70% (v/v) ethanol 
and stored at -20
o
C. 
X-Gal 
Twenty milligrams of X-Gal (5-bromo-4-chloro-3-indolyl β-D-galactopyranoside; Sigma-
Aldrich, MO, USA) was dissolved in 1ml of dimethyl formamide, wrapped in tin foil to protect 
the solution from light and stored at -20
o
C until needed.  
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1000X IPTG 
One hundred milligrams of IPTG (Isopropyl β-D-1-thiogalactopyranoside; Thermo-Scientific, 
MA, USA) was dissolved in 1ml of dH2O and filter sterilized through a 0.45μm filter. IPTG 
solution was stored at -20
o
C until needed. 
X-gal IPTG Ampicillin Plates 
LB agar plates were prepared as described above. Just before use, any excess moisture was 
removed from the surface of the agar by incubating the plates at 37
o
C with the lid slightly 
opened. To each plate, 40μl of X-Gal solution and 8μl of 1000X IPTG needed to be added. The 
solutions were premixed in the correct ratio to a final volume that was dependent on the number 
of plates included in the experiment. The solutions were thoroughly mixed and 48μl was added 
dropwise to the agar surface before being spread into an even thin layer. The plates were placed 
back into the incubator at 37
o
C until the surface was completely dry. The X-Gal/IPTG plates 
were prepared fresh just prior to the completion of the relevant transformation reactions.    
Procedure: 
Scaled-up Purification 
Plasmid DNA for mRNA production, subcloning and pDNA transfection was prepared and 
purified using the Qiagen
®
 Plasmid Purification Maxi Kit according to the manufacturer’s 
instructions and using the buffer system included in the kit. The average yield for a purification 
run was 2.5-3.5μg/μl in 50μl as measured on the NanoDrop 1000 (Thermo-Scientific, MA, USA) 
spectrophotometer. 
Small-scale Purification 
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Plasmid DNA purification for screening of positive clones during subcloning experiments was 
performed using EconoSpin
TM
 Prepacked Silica Membrane Spin Columns (Epoch Life Science 
Inc., TX, USA). The protocol followed was modified slightly from the manufacturer’s 
instructions but used the suggested buffer system prepared according to the provided recipes 
(table A2-1.1). The average yield for a purification run was 0.5-1.0 μg/μl in 30μl as measured on 
the NanoDrop 1000 (Thermo-Scientific, MA, USA) spectrophotometer.  
 
 
Table A2-1.1: Recipes for the buffer system used with the EconoSpin
TM
 Spin Columns for purification of pDNA 
 Description Recipe Storage  
Buffer MX1 Suspension Buffer 
 50mM Tris-HCl 
 10mM EDTA, pH 
8.0 (25
o
C) 
 100μg/ml RNAse A 
4
o
C 
Buffer MX2 Lysis Solution  
 0.2M NaOH 
 1% (w/v) SLS 
RT 
Buffer MX3 
Neutralization and Binding 
Solution 
 4M Guanidine 
hydrochloride  
 0.5M Potassium 
acetate 
 pH 4.2 (25oC) 
4
o
C 
Buffer WS Wash Buffer  
 10mM Tris-HCl, pH 
7.5 (25
o
C) 
 80% (v/v) Ethanol 
RT 
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Protocol:  
1. Harvested the bacterial pellet by centrifugation at 10 000rpm for 20 minutes at 4oC 
2. Discarded the supernatant and resuspended the pellet in 500μl of MX1 by pipette 
aspiration 
3. Added 500μl of MX2 and vigorously inverted tube until solution was homogenous and 
viscous 
4. Incubated the bacterial suspension for 5 minutes at RT 
5. Added 700μl of MX3 (ice-cold) and vigorously inverted tube until the cellular DNA 
became visibly fragmented and the remaining solution cleared 
6. Pelleted the fragmented cellular DNA by centrifugation at 12 000 rpm for 10 minutes at 
4
o
C and transferred the supernatant to an EconoSpin
TM
 column (800μl).  
7. Centrifuged the column for 1 minute at 4 000 rpm (at RT) and discarded the flow-through 
8. Added 500μl of WS Buffer to the column and centrifuged for 1 minute at 4 000 rpm at 
RT (repeated twice discarding the flow-through each time) 
9. Allowed the column to stand at RT for 5 minutes and then centrifuged at 12 000 rpm for 
2 minutes 
10. Transferred the column to a clean collection tube and added 25-30μl of dH2O and 
allowed to stand at RT for 5 minutes 
11. Eluted the pDNA by centrifugation at 12 000 rpm for 1.5 minutes  
12. Stored pDNA in aliquots at -20oC 
(Note: EconoSpin
TM
 Columns were stored between 4-8
o
C) 
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Overall Process: pDNA Preparation and Purification 
Table A2-1.2: Procedure followed when performing large-scale (Maxi Prep) and small-scale 
(Mini Prep) pDNA purification  
 Step Description  Maxi Prep Mini Prep 
D
a
y
 1
 
1. 
Transformation 
(see A2-2) 
 ~10ng of pDNA used to transform 50μl XL10 
Gold Escherichia coli competent bacteria 
 Plated full transformation volume (50μl) onto 
LB-agar plate and incubated overnight (OVN) a 
37
o
C (upside down) 
D
a
y
 2
 
2. 
Inoculation – 1 
colony per 
culture 
 100ml LB 
(100μg/ml 
ampicillin) 
 Incubated OVN at 
37
o
C with 160 rpm 
shaking  
 20ml LB (100μg/ml 
ampicillin) 
 Incubated OVN at 
37
o
C with 160 rpm 
shaking 
D
a
y
 3
 
3. 
pDNA 
Preparation and 
Purification 
 Qiagen® Plasmid 
Purification Maxi 
Kit 
 EconoSpinTM Column 
Protocol  
4.  Elution  50-100μl of dH2O  25-30μl of dH2O 
5.  Quantification 
 Used the NanoDrop 1000 Spectrophotometer  
 Recorded A260/A280 as a measure of purity 
(ratio of ~1.8 considered pure) 
6. 
Restriction 
Mapping 
 Confirmed pDNA identity using multiple 
restriction digest reactions  
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A2-2 Transformation Reaction Protocol 
Reagents 
1. Transformation Buffer I 
 10mM 2-(N-morpholino) ethanesulfonic acid (MES), pH5.8 at RT 
 10mM Rubidium chloride (RbCl2) 
 10mM Calcium chloride dihydrate (CaCl2.2H2O) 
 50mM Manganese tetrahydrate (MnCl2.4H2O) 
2. Transformation Buffer II 
 10mM Piperazine-N,N’-bis(2-ethanesulfonic acid) (PIPES), pH6.8 at RT 
 75mM CaCl2.2H2O 
 10mM RbCl2 
 3.75ml of 15% (v/v) Glycerol 
(Note: Transformation buffers were stored frozen at -20
o
C in aliquots and defrosted completely 
before use) 
Preparation of Competent Bacterial Cells  
1. A small volume of competent XL10 Gold® E. coli cells (Agilent Technologies, CA, USA) 
from frozen stock was used to inoculate 4ml of LB medium (no ampicillin) in a snap-cap 
plastic bacterial culture tube 
2. The inoculation was incubated OVN at 37oC with 160rpm shaking  
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3. The 4ml inoculation mix was then used to inoculate 100ml of LB (no ampicillin) which was 
then incubated until the OD550 ~ 0.4 (approximately 2 hours) 
4. The inoculation mix was then placed immediately on ice and chilled for 5 minutes 
5. The cells were pelleted by centrifugation at 4oC for 5 minutes at 2 500 xg 
6. The pellet was resuspended in Transformation Buffer I and left to chill on ice for another 5 
minutes 
7. The cells were pelleted again by centrifugation at 4oC for 5 minutes at 2 500 xg 
8. The pellet was resuspended in 2ml of Transformation Buffer II and left on ice for 15 minutes 
9. Cells were quickly dispensed in 100μl aliquots and stored immediately at -80oC 
Transformation Reaction 
1. An aliquot of chemically-competent XL10 Gold® cells was removed from storage and 
thawed on ice 
2. Once the cells had just thawed, a 50μl aliquot of competent cells was removed and incubated 
with ~10ng of pDNA on ice for 20 minutes 
3. The transformation reaction was then incubated at 42oC for 90 seconds and then immediately 
placed on ice for a further 2 minutes 
4. The transformation reaction was then plated on LB-agar plates (with 100μg/ml ampicillin) 
and incubated upside-down OVN at 37
o
C 
A2-3 Immunofluorescence Imaging Protocol  
Reagents 
1. 1X Phosphate-buffered Saline (PBS) 
 1 PBS tablet (Thermo-Scientific, MA, USA) was dissolved in 500ml dH2O 
 The solution was autoclaved - 1kPa, 121oC for 20 minutes 
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2. 4% (w/v) PFA 
 4g of PFA was dissolved in 80ml of 1X PBS in a water bath set at 60oC for approximately 2 
hours 
 While the solution was mixed by magnetic stirring, 1M NaOH was added dropwise until the 
solution cleared  
 The solution was allowed to cool to RT and then the pH was adjusted to 6.9 
 The final volume of 100ml was made up with 1X PBS 
3. 1% (w/v) BSA 
 Prepared fresh – 1g of BSA (Roche Diagnostics, Switzerland) was dissolved in a final 
volume of 1ml 1X PBS 
4. 0.1% (v/v) (Sigma-Aldrich, MO, USA) 
 Prepared fresh - 10μl of TritonTM-X100 was added to 10ml 1X PBS and mixed thoroughly 
5. 1000X DAPI 
 1mg of DAPI was dissolved in 1ml of dH2O 
 The 1000X DAPI solution was frozen and stored at -20oC until use  
Protocol 
1. Removed media from cells and immediately fixed the cells in 50μl of 4% PFA for 15 
minutes at RT 
2. Cells were washed 2X in phosphate buffered saline (PBS) and permeabilized by adding 50μl 
of 0.1% (v/v) Triton
TM
-X100 followed by a 10 minute incubation at RT 
3. Cells were again washed 2X in phosphate buffered saline (PBS) and either used immediately 
or stored in PBS at 4
o
C until needed 
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4. The cells were blocked in 1% (w/v) BSA either for 1 hour (condition 1 and condition 3) or 
overnight at 4
o
C (condition 2) and then washed 3X  
5. This was followed by the primary antibody incubation step – varied according the 
optimisation condition being tested for  
6. A stringent wash-step of 3X PBS washes was followed on by incubation with 30μl secondary 
antibody (diluted 1:200 in 1% (w/v) BSA) for 40 minutes at RT (in a humidity chamber) 
7. The cells were washed 3X in PBS and incubated in 1X DAPI for 5 minutes at RT  
8. The cells were washed a final 2X in PBS before imaging on the Zeiss Axio Imager 
Fluorescence Microscope (Zeiss, Germany) using the AxioVision Software V3.8.1 
A2-4 Formaldehyde-agarose gel electrophoresis  
Reagents 
1. 10X MOPS Buffer  
 0.2M 3-(N-morpholino) propanesulfonic acid (MOPS), pH7.0 at RT 
 20mM Sodium Acetate (NaOAc) 
 10mM Ethylenediaminetetraacetic acid (EDTA), pH 8.0 at RT  
2. DEPC-H2O 
 0.05% (v/v) diethyl pyrocarbonate (DEPC) in dH2O 
o Stirred for 30 minutes at RT using a magnetic stirrer bar 
o Autoclaved immediately – 1kPa, 121oC for 20 minutes  
Making the Formaldehyde-Agarose Gel 
1. For preparation of a 100ml gel at 1%, 1g of agarose was dissolved in 72ml of DEPC-H2O in 
a microwave oven  
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2. The melted agarose was allowed to cool to exactly 60oC as measured by a thermometer 
before the addition of 10ml 10X MOPS Buffer (final concentration of 1X) followed 
immediately by the addition of 18ml 32% Formaldehyde solution (Sigma-Aldrich, MO, 
USA). 
3. The gel was mixed, poured immediately into a setting tray with a 3mm comb and allowed to 
polymerise for a minimum of 30 minutes and a maximum of 60 minutes before loading the 
gel. 
Sample Preparation 
1. Approximately 500ng of mRNA was used per sample 
2. The mRNA was mixed with 8μl of 2X RNA Loading dye (Thermo-Scientific, MA, USA) 
and 1μl of 200μg/ml EtBr 
3. The samples were boiled at 70oC for 10 minutes and then immediately placed on ice until 
being loaded onto the gel 
Electrophoresis  
1. The gels were placed in an electrophoresis tank connected to a high capacity power pack in 
the cold room (2-8
o
C) 
2. MOPS Buffer (1X) was poured into the tank such as to just cover the top surface of the gel 
and fill up the sides 
3. The samples were loaded into their respective lanes 
4. The gel was electrophoresed at 80V for 45-60 minutes  
5. The gel was viewed as per a normal agarose gel  
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A3 ADDITIONAL EXPERIMENTAL DETAIL  
A3-1 PCR Thermal Cycler Profiles  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 2 3 4 5 6 7 
3:00 0:20 0:15 1:30 5:00 
95
o
C 
50
o
C 
72
o
C 72
o
C 
4
o
C 
X35 
eGFP, CMV and SHBs: 
LHBs: 
1 2 3 4 5 6 7 
3:00 0:20 0:15 2:15 5:00 
95
o
C 
55
o
C 
72
o
C 72
o
C 
4
o
C 
X35 
Profile Information: 
1. Initial denaturation step 
2. Denaturation 
3. Annealing 
4. Elongation 
5. Number of Cycles  
6. Final elongation step 
7. Baseline T  
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A3-2 Experimental process of subcloning  
 
1. Restriction digestion reactions: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Purification of desired DNA fragments by gel extraction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Ligation reactions: Used a vector/insert ratio of 1:3 based on molarity (0.172 pmole: 0.52 
pmole of available ends)– quantity of each fragment to be included in the reaction were 
calculated using table A3-3.1 
Extraction of sequence inserts from the 
positive pTZ clones (10μg per reaction): 
 eGFP/LHBs/SHBs – NcoI and PmeI  
 CMV – BstXI and SacI  
Linearization of vector backbone (10μg 
per reaction): 
 NcoI and PmeI – coding inserts 
Positive clones: 
 BstXI and SacI – CMV insertion 
  
 The total volume of the restriction digestion reactions were electrophoresed through a 1% agarose gel 
(120V, 35 minutes) 
 The gels were viewed directly by ultra-violet light (ethidium bromide staining of DNA) and the bands 
of correct sizes (run concurrently with GeneRuler
TM
 DNA Ladder Mix; Thermo-Scientific, MA, USA) 
were excised using a sharp, clean scalpel. 
 The DNA-containing gel slices were weighed and the DNA fragments purified using the MinElute® 
Gel Extraction Kit (Qiagen, Germany) according to the provided protocol in the kit manual. 
Fragments were eluted in 20μl of ddH2O 
 The purified fragments were quantified using the NanoDrop 1000 spectrophotometer (Thermo-
Scientific, MA, USA). 
 An elution check was done by gel electrophoresis (1% agarose, 120V, 35 minutes) loaded with 1μl of 
purified fragment eluent. Fragment identitiy was confirmed by size comparison with the DNA ladder. 
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Table A3-2.1: Calculation guideline for DNA fragment quantity included in ligation reactions. 
Amounts of DNA fragment included calculated according to fragment size and estimated weight. 
Adapted from the InsTAClone PCR Cloning Kit (Thermo-Scientific, MA, USA) manual 
Insert/vector backbone size (bp) 
Optimal quantity for inclusion in ligation 
reaction (ng)  
100 17 
300 51 
500 88 
1000 172 
2000 343 
3000 515 
4000 686 
5000 858 
 
 
 
 
 
 
 
 
 
 
125 | P a g e  
 
o Ligation was carried out using T4 DNA Ligase (Thermo-Scientific, MA, USA) and set-up as 
shown below: 
 
 NIC Experimental Reactions 
Needed Volumes (μl) 
Backbone According to table A3-2.1 
Insert  NONE According to table A3-2.1 
ddH2O  To make up VT = 30μl 
10X T4 DNA Ligase 
Buffer 
1X 3 3 
T4 DNA Ligase  1 1 
VT  30 30 
 
o Ligation reactions were incubated OVN (~16 hours) in a refrigerated water bath set to 
14
o
C 
 
4. Transformation of XL10 Gold® E. coli: 
i. Protocol followed according to A2-2: 2.5μl of each ligation reaction mix 
was used to transform 50μl of competent bacterial cells 
ii. Transformation reactions were plated onto standard LB-agar plates (A2-1) 
5. Screening for positive clones: 
i. Individual colonies were used to inoculate separate 20ml LB cultures (A2-
1) 
ii. Plasmid DNA was prepared using EconoSpinTM Spin Columns (A2-1) 
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iii. Restriction mapping was used to identify positive clones 
iv. DNA from positive clones was prepared on a large-scale and processed 
appropriately according to downstream application (A2-1) 
v. All plasmid DNA was stored at -20oC 
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A4 SUPPLEMENTARY DATA  
 
A4-1 mRNA Transcripts produced from template DNA linearised with SapI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A4-1: SapI linearisation of pmRNA-eGFP. The experiments shown are duplicates. SapI 
linearisation was performed under multiple conditions altered according to reacting amount of 
SapI included in the reaction and incubation time. Shown here are representative images of the 
(a) doublet consistently noted after linearisation with SapI and the (b) consequent heterogeneous 
mRNA preparation  
 
3000 
1000 
500 
pmRNA-CMV-eGFP 
a) eGFP mRNA b) 
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A4-2 Chromatogram representative of sequencing data 
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A5 ETHICS CLEARANCE AND INFORMATION 
A5-1 Biosafety approval for SA MRC/WITS-Antiviral Gene Therapy Research Unit 
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A5-2 Ethics clearance certificate  
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A5-3 M&E Document: Student-specific ethics clearance 
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